<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intravitreal steroids for macular edema in diabetes - Rittiphairoj, T - 2020 | Cochrane Library</title> <meta content="Intravitreal steroids for macular edema in diabetes - Rittiphairoj, T - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005656.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intravitreal steroids for macular edema in diabetes - Rittiphairoj, T - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005656.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005656.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Intravitreal steroids for macular edema in diabetes" name="citation_title"/> <meta content="Thanitsara Rittiphairoj" name="citation_author"/> <meta content="Johns Hopkins Bloomberg School of Public Health" name="citation_author_institution"/> <meta content="Tahreem A Mir" name="citation_author"/> <meta content="Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="Tianjing Li" name="citation_author"/> <meta content="University of Colorado Denver Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Gianni Virgili" name="citation_author"/> <meta content="gianni.virgili@unifi.it" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD005656.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005656.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005656.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005656.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents [*administration &amp; dosage]; Bevacizumab [administration &amp; dosage]; Bias; Confidence Intervals; Dexamethasone [administration &amp; dosage]; Diabetic Retinopathy [*complications]; Drug Implants; Fluocinolone Acetonide [administration &amp; dosage]; Glucocorticoids [administration &amp; dosage]; Intravitreal Injections; Macular Edema [*drug therapy, etiology]; Randomized Controlled Trials as Topic; Ranibizumab [administration &amp; dosage]; Steroids [*administration &amp; dosage]; Triamcinolone [administration &amp; dosage]; Vascular Endothelial Growth Factor A [antagonists &amp; inhibitors]; Visual Acuity [drug effects]; Vitreous Body" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005656.pub3&amp;doi=10.1002/14651858.CD005656.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005656\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005656\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005656.pub3",title:"Intravitreal steroids for macular edema in diabetes",firstPublishedDate:"Nov 17, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005656.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005656.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005656.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005656.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005656.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005656.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005656.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005656.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005656.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005656.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5456 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005656.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/appendices#CD005656-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/supinfo/CD005656StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/supinfo/CD005656StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intravitreal steroids for macular edema in diabetes</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#CD005656-cr-0004">Thanitsara Rittiphairoj</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#CD005656-cr-0005">Tahreem A Mir</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#CD005656-cr-0006">Tianjing Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information#CD005656-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Gianni Virgili</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information/en#CD005656-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005656.pub3">https://doi.org/10.1002/14651858.CD005656.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005656-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005656-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005656-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005656-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005656-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005656-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005656-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005656-abs-0001" lang="en"> <section id="CD005656-sec-0001"> <h3 class="title" id="CD005656-sec-0001">Background</h3> <p>Diabetic macular edema (DME) is secondary to leakage from diseased retinal capillaries with thickening of central retina, and is an important cause of poor central visual acuity in people with diabetic retinopathy. Intravitreal steroids have been used to reduce retinal thickness and improve vision in people with DME. </p> </section> <section id="CD005656-sec-0002"> <h3 class="title" id="CD005656-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of intravitreal steroid therapy compared with other treatments for DME. </p> </section> <section id="CD005656-sec-0003"> <h3 class="title" id="CD005656-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase on 15 May, 2019. We also searched reference lists, Science Citation Index, conference proceedings, and relevant trial registers. We conducted a top up search on 21 October, 2020. </p> </section> <section id="CD005656-sec-0004"> <h3 class="title" id="CD005656-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials that evaluated any type of intravitreal steroids as monotherapy against any other intervention (e.g. observation, laser photocoagulation, anti‐vascular endothelial growth factor (antiVEGF) for DME. </p> </section> <section id="CD005656-sec-0005"> <h3 class="title" id="CD005656-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed study eligibility and risk of bias and extracted data. Where appropriate, we performed meta‐analyses. </p> </section> <section id="CD005656-sec-0006"> <h3 class="title" id="CD005656-sec-0006">Main results</h3> <p>We included 10 trials (4348 participants, 4505 eyes). These trials compared intravitreal steroid therapies versus other treatments, including intravitreal antiVEGF therapy, laser photocoagulation, and sham injection. Most trials had an overall unclear or high risk of bias. </p> <p>One trial (701 eyes ) compared intravitreal dexamethasone implant 0.7mg with sham. We found moderate‐certainty evidence that dexamethasone leads to slightly more improvement of visual acuity than sham at 12 months (mean difference [MD] −0.08 logMAR, 95% confidence interval [CI] −0.12 to −0.05 logMAR). Regarding improvement of three or more lines of visual acuity, there was moderate‐certainty evidence in favor of dexamethasone at 12 months, but the CI covered the null value (risk ratio (RR) 1.39, 95% CI 0.91 to 2.12). Regarding adverse events, dexamethasone increased by about four times the risk of cataract progression and the risk of using intraocular pressure (IOP)‐lowering medications compared to sham (RR 3.89, 95% CI 2.75 to 5.50 and RR 4.54, 95% CI 3.19 to 6.46, respectively; moderate‐certainty evidence); about 4 in 10 participants treated with dexamethasone needed IOP‐lowering medications. </p> <p>Two trials (451 eyes) compared intravitreal dexamethasone implant 0.7mg with intravitreal antiVEGF (bevacizumab and ranibizumab). There was moderate‐certainty evidence that visual acuity improved slightly less with dexamethasone compared with antiVEGF at 12 months (MD 0.07 logMAR, 95% CI 0.04 to 0.09 logMAR; 2 trials; 451 participants/eyes; I<sup>2</sup> = 0%). The RR of gain of three or more lines of visual acuity was inconsistent between trials, with one trial finding no evidence of a difference between dexamethasone and bevacizumab at 12 months (RR 0.99, 95% CI 0.70 to 1.40; 1 trial; 88 eyes), and the other, larger trial finding the chances of vision gain were half with dexamethasone compared with ranibizumab (RR 0.50, 95% CI 0.32 to 0.79; 1 trial; 432 participants). The certainty of evidence was low. Cataract progression and the need for IOP‐lowering medications increased more than 4 times with dexamethasone implant compared to antiVEGF (moderate‐certainty evidence). </p> <p>One trial (560 eyes) compared intravitreal fluocinolone implant 0.19mg with sham. There was moderate‐certainty evidence that visual acuity improved slightly more with fluocinolone at 12 months (MD −0.04 logMAR, 95% CI −0.06 to −0.01 logMAR). There was moderate‐certainty evidence that an improvement in visual acuity of three or more lines was more common with fluocinolone than with sham at 12 months (RR 1.79, 95% CI 1.16 to 2.78). Fluocinolone also increased the risk of cataract progression (RR 1.63, 95% CI 1.35 to 1.97; participants = 335; moderate‐certainty evidence), which occurred in about 8 in 10 participants, and the use of IOP‐lowering medications (RR 2.72, 95% CI 1.87 to 3.98; participants = 558; moderate‐certainty evidence), which were needed in 2 to 3 out of 10 participants. </p> <p>One small trial with 43 participants (69 eyes) compared intravitreal triamcinolone acetonide injection 4 mg with sham. There may be a benefit in visual acuity at 24 months (MD −0.11 logMAR, 95% CI −0.20 to −0.03 logMAR), but the certainty of evidence is low. Differences in adverse effects were poorly reported in this trial. </p> <p>Two trials (615 eyes) compared intravitreal triamcinolone acetonide injection 4mg with laser photocoagulation and reached discordant results. The smaller trial (31 eyes followed up to 9 months) found more visual acuity improvement with triamcinolone (MD −0.18 logMAR, 95% CI −0.29 to −0.07 logMAR), but a larger, multicenter trial (584 eyes, 12‐month follow‐up) found no evidence of a difference regarding change in visual acuity (MD 0.02 logMAR, 95% CI ‐0.03 to 0.07 logMAR) or gain of three or more lines of visual acuity (RR 0.85, 95% CI 0.55 to 1.30) (overall low‐certainty evidence). Cataract progression was about three times more likely (RR 2.68, 95% CI 2.21 to 3.24; moderate‐certainty evidence) and the use of IOP‐lowering medications was about four times more likely (RR 3.92, 95% CI 2.59 to 5.96; participants = 627; studies = 2; I<sup>2</sup> = 0%; moderate‐certainty evidence) with triamcinolone. About 1 in 3 participants needed IOP‐lowering medication. </p> <p>One small trial (30 eyes) compared intravitreal triamcinolone acetonide injection 4mg with intravitreal antiVEGF (bevacizumab or ranibizumab). Visual acuity may be worse with triamcinolone at 12 months (MD 0.18 logMAR, 95% CI 0.10 to 0.26 logMAR); the certainty of evidence is low. Adverse effects were poorly reported in this trial. </p> <p>Four trials reported data on pseudophakic participants, for whom cataract is not a concern. These trials found no decrease in visual acuity in the second treatment year due to cataract progression. </p> </section> <section id="CD005656-sec-0007"> <h3 class="title" id="CD005656-sec-0007">Authors' conclusions</h3> <p>Intravitreal steroids may improve vision in people with DME compared to sham or control. Effects were small, about one line of vision or less in most comparisons. More evidence is available for dexamethasone or fluocinolone implants when compared to sham, and the evidence is limited and inconsistent for the comparison of dexamethasone with antiVEGF treatment. Any benefits should be weighed against IOP elevation, the use of IOP‐lowering medication and, in phakic patients, the progression of cataract. The need for glaucoma surgery is also increased, but remains rare. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005656-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005656-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005656-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005656-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005656-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005656-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005656-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005656-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005656-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005656-abs-0002" lang="en"> <h3>What are the benefits and risks of steroid injections for treating diabetic macular edema, a complication of diabetes? </h3> <p><b>Why this question is important</b><br/>Diabetes causes high levels of sugar in the blood. This can damage the small blood vessels at the back of the eye (the retina). If they leak, the central part of the retina (the macula) swells. This is called diabetic macular edema, and can cause blurred vision. If it is not treated, it can cause permanent vision loss. </p> <p>One way to treat this is to inject steroids (anti‐inflammatory medicines) into the eye. We reviewed the research evidence to compare the benefits and risks of this treatment against no treatment or other treatments. </p> <p><b>How we identified and assessed the evidence</b><br/>We searched for all relevant studies in the medical literature, compared their results, and summarized the evidence. We assessed how certain the evidence was for each finding, based on factors such as how well studies were conducted, study sizes, or consistency of findings across studies. We categorized the evidence as being of very low‐, low‐, moderate‐, or high‐certainty. </p> <p><b>What we found</b><br/>We identified 10 studies on 4348 people with diabetic macular edema. Participants were followed for nine to 36 months. The studies investigated three different injected steroids: dexamethasone, fluocinolone, and triamcinolone. Six studies were funded by pharmaceutical manufacturers. </p> <p><i>Benefits</i> (measured 12 or 24 months after treatment) </p> <p>Compared to a sham treatment:</p> <p>• Dexamethasone and fluocinolone probably improve visual sharpness and reduce thickness of the retina more; triamcinolone may also do this. </p> <p>• It is probable that more people’s vision improves by three lines or more on a vision chart with fluocinolone. Evidence is insufficient to tell whether dexamethasone or triamcinolone has the same effect. </p> <p>Compared to antiangiogenics (medicines that prevent new blood vessels forming behind the retina): </p> <p>• Dexamethasone probably improves visual sharpness similarly or slightly less but may reduce thickness of the retina slightly more. Triamcinolone may improve visual sharpness less too; we do not know how it affects thickness of the retina because the evidence is of very low‐certainty. </p> <p>• We cannot tell whether more people’s vision improves by three lines or more on a vision chart with dexamethasone or triamcinolone. This is because the evidence on dexamethasone is inconsistent and of low‐certainty, and no studies on triamcinolone evaluated this. </p> <p>Compared to laser therapy:</p> <p>• Triamcinolone may make little or no difference to whether people’s vision improves by three lines or more on a vision chart. </p> <p>• We do not know whether triamcinolone increases visual sharpness or reduces thickness of the retina more due to insufficient evidence. </p> <p><i>Risks</i> (measured nine to 36 months after treatment) </p> <p>Compared to a sham treatment:</p> <p>• It is probable that cataracts progress in more people with dexamethasone or fluocinolone; cataract may be more likely with triamcinolone too. </p> <p>• It is probable that more people treated with dexamethasone or fluocinolone need drops that lower eye pressure. The evidence is too imprecise to show if triamcinolone affects the need for such drops. </p> <p>• Fluocinolone may increase the risk of needing surgery for glaucoma (optic nerve damage caused by high pressure in the eye). There is insufficient evidence to show if dexamethasone or triamcinolone affects the need for glaucoma surgery. </p> <p>Compared to antiangiogenics:</p> <p>• Cataract progression and the need for pressure‐lowering eye drops is probably greater with dexamethasone. </p> <p>•We do not know if dexamethasone affects the need for glaucoma surgery because the evidence is poor and imprecise. </p> <p>•There is insufficient evidence to show if triamcinolone causes more adverse effects.</p> <p>Compared to laser therapy:</p> <p>• Cataract progression and the need for pressure‐lowering eye drops is probably greater with triamcinolone. </p> <p>• The evidence is too imprecise to show how triamcinolone affects the need for glaucoma surgery. </p> <p><b>What this means</b><br/>Evidence of low‐ to moderate‐certainty suggests that: </p> <p>‐ steroids may be, or probably are, more effective than a sham treatment;</p> <p>‐ steroids may be, or probably are, less effective at improving visual sharpness than antiangiogenics; </p> <p>‐ steroids may, or probably, increase the risk of cataract progression and elevated eye pressure. </p> <p><b>How up‐to‐date is the review?</b> <br/>The evidence in this Cochrane Review is current to 15 May 2019. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005656-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005656-sec-0090"></div> <h3 class="title" id="CD005656-sec-0091">Implications for practice</h3> <section id="CD005656-sec-0091"> <p>Our analysis suggests that intravitreal steroid injections and implants may improve vision in people with diabetic macular edema (DME). However, their efficacy relative to anti‐vascular endothelial growth factor (antiVEGF) drugs is less clear and might be similar or lower. Regarding adverse events, intraocular pressure (IOP)‐lowering medications were needed in about one‐third of cases after receiving intravitreal steroids. There was a small risk of undergoing glaucoma surgery within 24 months in the trial on fluocinolone implant; the fluocinolone implant also has a long‐term sustained effect on both visual acuity and IOP. </p> <p>Subgroup data support the use of intravitreal steroids in pseudophakic patients, in whom the development of cataract, usually occurring after one year, is not a factor that limits sustained visual improvement. Additionally, subgroup data supported the use of intravitreal fluocinolone in individuals with chronic DME. Both these restrictions have been variably incorporated in the labels approved by national and international drug agencies. </p> <p>We did not collect economic data, specifically on the cost‐effectiveness and usability of steroids versus different antiVEGF drugs, including bevacizumab, in different settings, including low‐middle income countries. </p> </section> <h3 class="title" id="CD005656-sec-0092">Implications for research</h3> <section id="CD005656-sec-0092"> <p>Unanswered questions remain on whether intravitreal steroids or antiVEGF drugs are more effective and/or safe, depending on DME subtype, and particularly in individuals with long‐standing DME. Economic and quality of life data are also needed. The risk and severity of adverse events and how best to manage them for specific patients will determine the value of these treatments. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005656-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005656-sec-0008"></div> <div class="table" id="CD005656-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravitreal dexamethasone implant 0.7 mg compared to sham for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal dexamethasone implant 0.7 mg compared to sham for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal dexamethasone implant 0.7 mg<br/><b>Comparison:</b> sham </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal dexamethasone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity ‐ 12 months was 0.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.08 better<br/>(−0.12 better to −0.05 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE 1 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000<br/>(86 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.39<br/>(0.91 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE 1 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change of retinal thickness ‐ 36 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness (micron) ‐ 36 months was −51.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −81 micron</p> <p>(−100 to −63 micron)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000</p> <p>(267 to 534)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.89</p> <p>(2.75 to 5.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000</p> <p>(292 to 591)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.54</p> <p>(3.19 to 6.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(1 to 43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.04</p> <p>(0.59 to 42.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>2</sup>Downgraded −1 for risk of bias: large loss to follow‐up. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005656-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravitreal dexamethasone implant 0.7 mg compared to intravitreal antiVEGF for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal dexamethasone implant 0.7 mg compared to intravitreal antiVEGF for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal dexamethasone implant 0.7 mg<br/><b>Comparison:</b> intravitreal antiVEGF </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of eyes<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal antiVEGF</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal dexamethasone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity ‐ 12 months was −0.16.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 worse<br/>(0.04 worse to 0.09 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Inconsistent findings: one trial finding no evidence of a difference between dexamethasone and bevacizumab at 12 months (RR 0.99, 95% CI 0.70 to 1.40; 1 trial; 88 eyes), and the other found the chances of vision gain were half with dexamethasone compared with ranibizumab (RR 0.50, 95% CI 0.32 to 0.79; 1 trial; 432 eyes). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness ‐ 12 months was −140.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −21.09 thinner<br/>(−41.9 thinner to −0.28 thinner) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> <p>(68 to 246)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.23</p> <p>(2.36 to 7.59)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE 1 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> <p>(234 to 659)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.76</p> <p>(2.84 to 7.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> <p>(26 to 44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.02</p> <p>(0.12 to 73.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>antiVEGF:</b> anti‐vascular endothelial growth factor agent; <b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high or unclear risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>3</sup>Downgraded −1 for inconsistency: heterogeneous results of two trials.<br/><sup>4</sup>Downgraded −2 for imprecision: very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005656-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Intravitreal fluocinolone acetonide implant 0.19 mg compared to sham for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal fluocinolone implant 0.19 mg compared to sham for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal fluocinolone acetonide implant 0.19 mg<br/><b>Comparison:</b> sham </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal fluocinolone implant</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity was −0.04.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.04 better<br/>(−0.06 better to −0.01 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000<br/>(138 to 331) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.79<br/>(1.16 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness was −67.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −76.00 thinner</p> <p>(−94.31 thinner to −57.69 thinner)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>815 per 1000<br/>(675 to 985) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.63<br/>(1.35 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000</p> <p>(384 to 562)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.72</p> <p>(1.87 to 3.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>558<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> <p>(7 to 385)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 9.54</p> <p>(1.28 to 70.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>558<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: unclear risk of bias for most domains.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005656-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to sham for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal triamcinolone acetonide injection 4 mg compared to sham for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal triamcinolone acetonide injection 4 mg<br/><b>Comparison:</b> sham </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of eyes<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal triamcinolone injection</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 24 months**</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity was −0.02.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.11 better<br/>(−0.20 better to −0.03 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 24 months**</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/>(14 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.12<br/>(0.48 to 34.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron) ‐ 24 months**</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness was −71.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −59 thinner<br/>(−103.5 thinner to −14.5 thinner) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000<br/>(139 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/>(0.97 to 9.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000</p> <p>(384 to 562)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 21.60</p> <p>(1.32 to 354.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No surgeries were recorded in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**No data available at 12 months. </p> <p><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>3</sup>Downgraded −2 for imprecision: very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005656-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to macular laser for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal triamcinolone acetonide injection 4 mg compared to macular laser for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal triamcinolone acetonide injection 4 mg<br/><b>Comparison:</b> macular laser </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of eyes<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with macular laser</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal triamcinolone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>1 small study (31 participants) reported data favoring triamcinolone at 9 months (MD −0.18, 95% CI −0.29 to −0.07), and data from a large, multicenter study (584 eyes) favored macular laser at 12 months (MD 0.02, 95% CI −0.03 to 0.07). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> <p>(77 to 182)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85</p> <p>(0.55 to 1.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>584</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron)</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>1 small study (31 participants) reported data favoring triamcinolone at 9 months (MD −83.00, 95% CI −171.60 to −5.60), and data from a large, multicenter study (454 participants) found no difference between groups at 12 months (MD 5.00, 95% CI −18.76 to 28.76). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 9 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>767 per 1000<br/>(633 to 927) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.68</p> <p>(2.21 to 3.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 9 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>279 per 1000</p> <p>(184 to 425)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.92</p> <p>(2.59 to 5.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 9 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> <p>(1 to 216)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.68 (0.63 to 216)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −2 for inconsistency: significant heterogeneity between studies.<br/><sup>3</sup>Downgraded −1 for imprecision: large confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005656-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to antiVEGF for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal triamcinolone acetonide injection 4 mg compared to antiVEGF for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal triamcinolone acetonide injection 4 mg<br/><b>Comparison:</b> antiVEGF </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antiVEGF</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal triamcinolone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity ‐ 12 months was −0.12 logMAR.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.18 worse<br/>(0.10 worse to 0.26 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in central retinal thickness (micron) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Inconsistent, non‐significant effects were found for triamcinolone versus bevacizumab or ranibizumab. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data reported on IOP‐lowering medications, but the authors state that there was no difference in IOP change in the triamcinolone and bevacizumab groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No surgery for glaucoma reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>antiVEGF:</b> anti‐vascular endothelial growth factor agent; <b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>3</sup>Downgraded −2 for inconsistency: heterogeneous results of two antiVEGF study arms. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005656-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005656-sec-0009"></div> <section id="CD005656-sec-0010"> <h3 class="title" id="CD005656-sec-0010">Description of the condition</h3> <p>Diabetic macular edema (DME) is caused by diabetic retinopathy (DR), the most frequent and severe ocular complication of diabetes mellitus. DR is the leading cause of blindness in the working‐age population in high‐income countries (<a href="./references#CD005656-bbs2-0112" title="LeeR , WongTY , SabanayagamC . Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond)2015;2:17.">Lee 2015</a>; <a href="./references#CD005656-bbs2-0111" title="LeasherJL , BourneRR , FlaxmanSR , JonasJB , KeeffeJ , NaidooK , et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care2016;39(9):1643-9.">Leasher 2016</a>; ). DME is the swelling of the retina resulting from the exudation and accumulation of extracellular fluid and proteins in the macula (<a href="./references#CD005656-bbs2-0097" title="CiullaTA , AmadorAG , ZinmanB . Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care2003;26(9):2653-64.">Ciulla 2003</a>), due to the breakdown of the blood‐retina barrier with an increase in vascular permeability (<a href="./references#CD005656-bbs2-0094" title="AntcliffRJ , MarshallJ . The pathogenesis of edema in diabetic maculopathy. Seminars in Ophthalmology1999;14(4):223-32.">Antcliff 1999</a>). The prevalence of DR increases with diabetes duration, hemoglobin A1C, and blood pressure levels, and is higher in people with type 1 compared with type 2 diabetes (<a href="./references#CD005656-bbs2-0125" title="YauJW , RogersSL , KawasakiR , LamoureuxEL , KowalskiJW , BekT , et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012;35(3):556-64.">Yau 2012</a>). About a third of people with diabetes have DR, and 1 in 10 is affected by DME (<a href="./references#CD005656-bbs2-0125" title="YauJW , RogersSL , KawasakiR , LamoureuxEL , KowalskiJW , BekT , et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012;35(3):556-64.">Yau 2012</a>). Intraretinal fluid accumulation results in significant reduction in visual acuity that may be reversible in the short term, but prolonged edema can cause irreversible damage resulting in permanent visual loss. </p> <section id="CD005656-sec-0011"> <h4 class="title">Clinical presentation and diagnosis</h4> <p>The most common presenting clinical symptom of DME is blurred vision. Other symptoms can include metamorphopsia (distortion of visual image), floaters, change in contrast sensitivity, photophobia (visual intolerance to light), changes in color vision, and scotomas (localized defects of visual field). </p> <p>The diagnosis is made by finding macular edema due to diabetes on the clinical examination. Generally this requires direct visualization of the macular edema that uses a high magnification stereoscopic lens system designed to view the ocular fundus. A fundus contact lens is probably most typically used for this purpose, but other non‐contact lenses can also be used. If the thickening is sufficiently severe it can be seen with an indirect ophthalmoscope. Chronic DME can be associated with cystoid macular edema (CME), cystic degeneration of the macular retina. If CME is present, it might be visible with a handheld non‐stereoscopic direct ophthalmoscope. Although stereoscopic observation of the fundus is considered to be the most accepted method of diagnosing DME, there is an increased use of other diagnostic tools such as stereo fundus photography, fluorescein angiography, and more recently, optical coherence tomography (<a href="./references#CD005656-bbs2-0122" title="VirgiliG , MenchiniF , CasazzaG , HoggR , DasRR , WangX , et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database of Systematic Reviews2011, Issue 6. Art. No: CD008081. [DOI: 10.1002/14651858.CD008081.pub2]">Virgili 2011</a>). </p> </section> </section> <section id="CD005656-sec-0012"> <h3 class="title" id="CD005656-sec-0012">Description of the intervention</h3> <p>In addition to glycemic and blood pressure control (<a href="./references#CD005656-bbs2-0100" title="DoDV , WangX , VedulaSS , MarroneM , SleilatiG , HawkinsBS , et al. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD006127. [DOI: 10.1002/14651858.CD006127.pub2]">Do 2015</a>), currently the most common treatment option for DME is intravitreal injection of antiangiogenic, or anti‐vascular endothelial growth factor (antiVEGF), drugs, which needs to be repeated over many years (<a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a>; <a href="./references#CD005656-bbs2-0123" title="VirgiliG , ParravanoM , EvansJR , GordonI , LucenteforteE . Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub5]">Virgili 2017</a>). Other treatments for DR and its complications, including DME, are laser photocoagulation, intravitreal steroids, and vitrectomy (<a href="./references#CD005656-bbs2-0101" title="Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of DRS findings. Ophthalmology1978;85(1):82-106.">DRS 1978</a>; <a href="./references#CD005656-bbs2-0102" title="Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Archives of Ophthalmology1985;103(12):1796-806.">ETDRS 1985</a>; <a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a>; <a href="./references#CD005656-bbs2-0104" title="EvansJR , MichelessiM , VirgiliG . Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD011234. [DOI: 10.1002/14651858.CD011234.pub2]">Evans 2014</a>; <a href="./references#CD005656-bbs2-0110" title="JorgeEC , JorgeEN , BotelhoM , FaratJG , VirgiliG , El DibR . Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD010859. [DOI: 10.1002/14651858.CD010859.pub2]">Jorge 2018</a>; <a href="./references#CD005656-bbs2-0113" title="Martinez-ZapataMJ , Marti-CarvajalAJ , SolaI , PijoanJI , Buil-CalvoJA , CorderoJA , et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD008721. [DOI: 10.1002/14651858.CD008721.pub2]">Martinez‐Zapata 2014</a>; <a href="./references#CD005656-bbs2-0114" title="MehtaH , HenningsC , GilliesMC , NguyenV , CampainA , Fraser-BellS . Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD011599. [DOI: 10.1002/14651858.CD011599.pub2]">Mehta 2018</a>; <a href="./references#CD005656-bbs2-0115" title="MoutrayT , EvansJR , LoisN , ArmstrongDJ , PetoT , Azuara-BlancoA . Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2018, Issue 3. Art. No: CD012314. [DOI: 10.1002/14651858.CD012314.pub2]">Moutray 2018</a>; <a href="./references#CD005656-bbs2-0121" title="SmithJM , SteelDH . Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews2015, Issue 8. Art. No: CD008214. [DOI: 10.1002/14651858.CD008214.pub3]">Smith 2015</a>). </p> <p>Laser photocoagulation is a therapeutic technique that uses a strong light source to coagulate tissue. The Early Treatment Diabetic Retinopathy Study (ETDRS) recommended direct focal photocoagulation for focal macular edema and grid photocoagulation for diffuse macular edema (<a href="./references#CD005656-bbs2-0102" title="Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Archives of Ophthalmology1985;103(12):1796-806.">ETDRS 1985</a>). In patients with DME, vitrectomy is considered when this is associated with a thickened, taut, posterior hyaloid (<a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a>). </p> <p>Intravitreal steroids have been investigated for posterior segment disorders such as DME for their angiostatic and antipermeability properties. For DME, intravitreal delivery techniques (intravitreal injection and steroids implant) allow for sufficiently high local concentrations of steroids to maximize their anti‐inflammatory, angiostatic, and antipermeability effects in treating DME while minimizing systemic toxicity (<a href="./references#CD005656-bbs2-0098" title="CiullaTA , WalkerJD , FongDS , CriswellMH . Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Current Opinions in Ophthalmology2004;15(3):211-20.">Ciulla 2004</a>). Moreover, the frequency of intravitreal injections is lower with steroids compared with antiVEGF drugs (<a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a>). Intravitreal triamcinolone acetonide (4 mg) has generally been used as an off‐label drug in most settings. On‐label intravitreal injections of steroid implants, such as dexamethasone (Ozurdex 0.7 mg, Allergan plc, Dublin, Ireland) and fluocinolone acetonide (Alimera Sciences, Inc., Atlanta, GA, and Psivida, Inc., Watertown, MA), are also delivered with an intravitreal injection. </p> </section> <section id="CD005656-sec-0013"> <h3 class="title" id="CD005656-sec-0013">How the intervention might work</h3> <p>Steroids represent the traditional treatment of inflammatory eye disease because of their ability to diminish neutrophil transmigration, limit access to sites of inflammation, and decrease cytokine production. </p> </section> <section id="CD005656-sec-0014"> <h3 class="title" id="CD005656-sec-0014">Why it is important to do this review</h3> <p>Intravitreal injections of antiVEGF drugs are the most commonly used treatment for DME, but the injections need to be repeated (<a href="./references#CD005656-bbs2-0123" title="VirgiliG , ParravanoM , EvansJR , GordonI , LucenteforteE . Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD007419. [DOI: 10.1002/14651858.CD007419.pub5]">Virgili 2017</a>). Laser photocoagulation is seldom used nowadays because vision is maintained but not improved. Other less invasive laser techniques are under investigation, which limit any thermal damage to the retina while potentially maintaining efficacy in treating DME (<a href="./references#CD005656-bbs2-0110" title="JorgeEC , JorgeEN , BotelhoM , FaratJG , VirgiliG , El DibR . Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD010859. [DOI: 10.1002/14651858.CD010859.pub2]">Jorge 2018</a>). Steroids administered intravitreally have been investigated to treat DME and have been recommended in patients who are pseudophakic or when DME is resistant to antiVEGF drugs (<a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a>). <a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a> observed that the most common commercial formulation of triamcinolone acetonide is not approved by the US US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat DME and should be used only in patients where the approved agents for this indication are unavailable. </p> <p>The benefits of intravitreal steroids should be balanced with the harms, since both topical and intraocular steroids can cause cataract and increase intraocular pressure (IOP). </p> <p>A systematic review was therefore needed to examine the evidence regarding the effectiveness and safety of intravitreal steroids compared to other treatments for DME. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005656-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005656-sec-0015"></div> <p>To assess the effectiveness and safety of intravitreal steroid therapy compared with other treatments for DME. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005656-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005656-sec-0016"></div> <section id="CD005656-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005656-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials that planned to follow up participants for nine months or more. The duration of follow‐up was a change to the original protocol, because the efficacy of intravitreal treatments with steroids and antiVEGF drugs are well established, and we were interested in long‐term effects. We excluded randomized cross‐over trials due to the substantial carry‐over effect associated with intravitreal steroids. </p> </section> <section id="CD005656-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included trials that had enrolled participants of any age and sex with any type of DME (focal, diffuse, CME) as diagnosed in the trial. Trials in which participants were non‐responsive to previous therapy (i.e. laser photocoagulation) or had no prior treatment were eligible for inclusion. We expected that most included trials would have been conducted in eye clinics, especially in retina services. </p> </section> <section id="CD005656-sec-0020"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing intravitreal steroid therapy (intravitreal injection or surgical implantation) of any dosage and duration with other treatments for DME (e.g. observation, laser photocoagulation, antiVEGF agents). When multiple doses were used in a trial, we extracted data on the commercially available dose. We excluded dosing studies in which no control or comparator was used. We also excluded trials in which steroids were given as part of combination therapy (e.g. laser photocoagulation plus intravitreal steroids versus other treatments) because such an intervention was the subject of another Cochrane Review (<a href="./references#CD005656-bbs2-0114" title="MehtaH , HenningsC , GilliesMC , NguyenV , CampainA , Fraser-BellS . Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD011599. [DOI: 10.1002/14651858.CD011599.pub2]">Mehta 2018</a>). In the current version of the review we also excluded Retisert, a fluocinolone acetonide intravitreal implant (Bausch and Lomb Inc., Bridgewater, NJ). Retisert was developed for non‐infectious uveitis and was not approved by the regulatory bodies for DME. </p> </section> <section id="CD005656-sec-0021"> <h4 class="title">Types of outcome measures</h4> <section id="CD005656-sec-0022"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome was visual acuity (VA), assessed as: (1) the change from baseline of best‐corrected visual acuity (BCVA) as continuous data (converted into logMAR); and (2) three or more lines improvement from baseline (ETDRS, Snellen, or logMAR equivalent; one line improvement analyzed if three lines not available). The primary time point for assessment was 12 months, plus or minus three months of follow‐up. We also included longer times of follow‐up as reported by the included trials. The mean VA changes is the current primary outcome in newer studies on DME. </p> <p>The minimal clinically important different for change in BCVA was 0.1 logMAR (five ETDRS letters or one Snellen line); for the three‐ and one‐line improvement, it was a risk ratio of 1.33. </p> </section> <section id="CD005656-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcome was mean change in retinal thickness from baseline as measured by optical coherence tomography (OCT). We examined the secondary outcome at 12 months, plus or minus three months, and at subsequent follow‐up times as reported by the included trials. </p> <section id="CD005656-sec-0024"> <h6 class="title">Adverse effects</h6> <p>Ocular adverse effects of interest were those related to steroids use (<a href="./references#CD005656-bbs2-0103" title="Schmidt-ErfurthU , Garcia-ArumiJ , BandelloF , BergK , ChakravarthyU , GerendasBS , et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica2017;237(4):185–222.">EURETINA 2017</a>), at the longest available follow‐up: </p> <p> <ol id="CD005656-list-0001"> <li> <p>cataract formation or progression (as defined by the trialists) or cataract surgery;</p> </li> <li> <p>ocular hypertension, as defined by the trialists;</p> </li> <li> <p>use of IOP‐lowering medications;</p> </li> <li> <p>glaucoma surgery.</p> </li> </ol> </p> <p>We also planned to examine legal blindness (visual acuity of 20/200 or worse in the better eye with corrective lenses or visual field restriction to 20 degrees diameter or less (tunnel vision) in the better eye). We did not record systemic adverse effects since these are not expected to be related to intravitreal steroid. </p> </section> <section id="CD005656-sec-0025"> <h6 class="title">Quality of life measures</h6> <p>We planned to compare data on quality of life by any validated measures when reported in the included trials. </p> </section> <section id="CD005656-sec-0026"> <h6 class="title">Economic data</h6> <p>We did not plan to extract economic data in this review update; in fact, no cost‐analysis was incorporated in the included trials, and a review focusing on costs should have considered and modeled the burden of drug cost and injection frequency, but also that of IOP medical and surgical control as well as cataract extraction. This was beyond the scope of this review. </p> </section> </section> <section id="CD005656-sec-0027"> <h5 class="title">Follow‐up</h5> <p>We included trials in which participants were followed for nine months or more.</p> </section> <section id="CD005656-sec-0028"> <h5 class="title">Outcomes presented in the 'Summary of findings' table</h5> <p>We presented the following outcomes in the 'Summary of findings' table.</p> <p> <ul id="CD005656-list-0002"> <li> <p>Visual acuity outcomes: change from baseline (logMAR) and improvement by three or more lines. </p> </li> <li> <p>Change in central retinal thickness (micron).</p> </li> <li> <p>Ocular adverse events:</p> <ul id="CD005656-list-0003"> <li> <p>proportion of participants with cataract formation or progression;</p> </li> <li> <p>proportion of participants needing IOP‐lowering medications;</p> </li> <li> <p>surgery for glaucoma.</p> </li> </ul> </li> <li> <p>Quality of life.</p> </li> </ul> </p> <p>We used GRADE methodology to assess the certainty of evidence for each outcome for each comparison, following the guidance in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005656-bbs2-0120" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , GuyattGH . Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.. Cochrane, 2019.">Schunemann HJ 2019</a>). </p> </section> </section> </section> <section id="CD005656-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005656-sec-0030"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases for randomized controlled trials and controlled clinical trials. There were no restrictions on language or year of publication. The date of the search was 15 May 2019. </p> <p> <ul id="CD005656-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 5) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 15 May 2019) (<a href="./appendices#CD005656-sec-0096">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 15 May 2019) (<a href="./appendices#CD005656-sec-0097">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 15 May 2019) (<a href="./appendices#CD005656-sec-0098">Appendix 3</a>). </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 15 May 2019) (<a href="./appendices#CD005656-sec-0099">Appendix 4</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 15 May 2019) (<a href="./appendices#CD005656-sec-0100">Appendix 5</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 15 May 2019) (<a href="./appendices#CD005656-sec-0101">Appendix 6</a>). </p> </li> </ul> </p> <p>We conducted a top up search on 21 October, 2020.</p> </section> <section id="CD005656-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of the included trials for additional trials. We used Science Citation Index to find trials that had cited the included trials. We also contacted experts in the field for information on current, past, or unpublished trials. We handsearched conference proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO, year 2002 to 2006) and the Macular Society Annual Meeting (year 2005 and 2006) for the purposes of this review. We also handsearched <i>Ophthalmology Times</i>. </p> </section> </section> <section id="CD005656-sec-0032"> <h3 class="title" id="CD005656-sec-0032">Data collection and analysis</h3> <section id="CD005656-sec-0033"> <h4 class="title">Selection of studies</h4> <p>At least two review authors independently assessed the titles and abstracts resulting from the electronic and manual searches to ascertain relevant studies for inclusion. We assessed each record identified by the searches as 'definitely relevant,' 'potentially relevant,' or 'not relevant.' Any discrepancies were resolved by discussion. We obtained the full‐text reports of all potentially or definitely relevant records. At least two review authors worked independently to determine the final eligibility of each trial. Any discrepancies were resolved by discussion. We documented the excluded studies and the reasons for their exclusion (see <a href="./references#CD005656-sec-0112" title="">Characteristics of excluded studies</a>). When further information was needed to determine eligibility of a trial, we contacted the trialists. If no response was received within two weeks, we assessed the trial based on the available information. </p> <p>For the 2019 update, we used <a href="./references#CD005656-bbs2-0099" title="Covidence systematic review software. Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org, Used in 2019-2020.">Covidence</a> to manage the study selection process. </p> </section> <section id="CD005656-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data onto data extraction forms developed by the Cochrane Eyes and Vision. We extracted the following study characteristics: study design and methods, participants' characteristics, interventions, outcomes, adverse events, and other relevant information. Any discrepancies between authors were resolved by discussion. We contacted the trialists for missing data. One review author entered all data into Review Manager 5 (RevMan 5) (<a href="./references#CD005656-bbs2-0117" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), and a second review author verified the data entered. </p> </section> <section id="CD005656-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias of the included trials according to the guidelines in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005656-bbs2-0108" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019b</a>). We considered five 'Risk of bias' domains: selection bias (random sequence generation and allocation concealment), performance bias (masking of participants and study personnel), detection bias (masking of outcome assessors), attrition bias (completeness of follow‐up and intention‐to‐treat analysis), and reporting bias (selective outcome reporting). We also assessed studies for other potential sources of bias such as sources of funding and trialists' conflicts of interest. </p> <p>We graded each trial as at low, high, or unclear risk of bias for each domain. Any disagreements between authors were resolved by discussion or adjudication with a third review author, or both. We contacted trialists to clarify methodological details when information to judge risk of bias was unclear or not reported. </p> </section> <section id="CD005656-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated a summary risk ratio (RR) with corresponding 95% confidence interval (CI). Dichotomous outcomes included the proportion with more than one or three lines improvement in visual acuity from baseline, and the proportion experiencing an adverse event. </p> <p>For continuous outcomes, we calculated the mean difference (MD) with corresponding 95% CI. Continuous outcomes included mean change in best‐corrected visual acuity (converted into logMAR) and mean change in retinal thickness from baseline. </p> <p>The included trials comprised a mixture of change from baseline and final values; we combined these in meta‐analysis when appropriate. We planned to analyze quality of life and economic data as continuous outcomes when data were available. </p> </section> <section id="CD005656-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>We assessed whether the trialists randomized and analyzed at the participant level or at the eye level. In trials in which both eyes were randomized, we planned to extract data from analyses that accounted for the correlation between the two eyes. In this update, we included in the analysis studies in which both eyes of some participants were randomized (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>). In our GRADE assessment we considered them as contributing to imprecision if no adjustment for correlation was used. We did not find any cluster‐randomized trials in this update. When trials reported data on more than one steroid dose, we extracted data on the commercial dose for analyses (e.g. dexamethasone 0.7 mg instead of 0.35 mg). </p> </section> <section id="CD005656-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing or unclear, we contacted trialists for information or clarification, or both. We allowed two weeks for response, after which if no response was received, we assessed the data that were available. We did not impute missing data for the purposes of this review. </p> </section> <section id="CD005656-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>Before combining data from individual trials, we qualitatively assessed clinical and methodological heterogeneity by examining the characteristics of each trial. When trials were homogeneous with respect to participant population, interventions compared, and outcomes, we further examined statistical heterogeneity among trials using the forest plots, the results of the Chi<sup>2</sup> test, and the value of I<sup>2</sup> statistics. We interpreted a Chi<sup>2</sup> P &lt; 0.1 as significant statistical heterogeneity, and considered an I<sup>2</sup> value &gt; 60% to indicate substantial statistical heterogeneity. </p> </section> <section id="CD005656-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed each included trial for selective outcome reporting by comparing the outcomes specified in trial protocols or trial registries (when available) with the outcomes reported in published trial reports. We planned to assess for small‐study effect, which could be due to publication bias, by examining the asymmetry of funnel plots when 10 or more trials were included in meta‐analysis. </p> </section> <section id="CD005656-sec-0041"> <h4 class="title">Data synthesis</h4> <p>We followed the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005656-bbs2-0107" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019a</a>). When no substantial clinical or methodological heterogeneity was detected, we combined the results in a meta‐analysis. We used a random‐effects model unless fewer than three trials were included, in which case we used a fixed‐effect model. If substantial heterogeneity was observed, we presented the results in a tabulated summary. </p> </section> <section id="CD005656-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not perform subgroup analyses according to dose of triamcinolone, diabetes type, macular edema type, duration of diabetes (less than five years, five to 30 years, more than 30 years), insulin use, baseline VA, and route of steroid administration due to insufficient data. We were also unable to perform subgroup analyses based on whether eyes were pseudophakic because no comparative data were available for both phakic and pseudophakic patients; we summarized such data narratively. These data are relevant since the European Medical Agency (EMA) has approved intravitreal dexamethasone implant 0.7 mg to treat visual impairment due to DME in people who are pseudophakic or who are considered insufficiently responsive to or unsuitable for non‐corticosteroid therapy. </p> </section> <section id="CD005656-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>We did not conduct sensitivity analysis to determine the impact of exclusion of trials with high risk of bias, unpublished data, and industry‐funded trials. Instead, we qualitatively evaluated the influence of these trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005656-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005656-sec-0044"></div> <section id="CD005656-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD005656-sec-0046"> <h4 class="title">Results of the search</h4> <p>The original review published in 2008 included seven trials (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>; <a href="./references#CD005656-bbs2-0013" title="AudrenF , ErginayA , HaouchineB , BenosmanR , ConrathJ , BergmannJF , et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmologica Scandinavica2006;84(5):624-30. MassinP , AudrenF , HaouchineB , ErginayA , BergmannJF , BenosmanR , et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology2004;111(2):218-24. MassinPG , AudrenF , ErginayA , HaouchineB , BergmannJF , GaudricA . Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: results of a prospective controlled trial. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 3463. ">Audren 2006</a>; <a href="./references#CD005656-bbs2-0042" title="JonasJB , KampperterBA , HarderB , VossmerbaeumerU , SauderG , SpandauUH . Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. Journal of Ocular Pharmacology and Therapeutics2006;22(3):200-7. ">Jonas 2006</a>; <a href="./references#CD005656-bbs2-0050" title="BlumenkranzMS , HallerJA , KuppermannBD , WilliamsGA , IpM , DavisM , et al. Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina2010;30(7):1090-4. HallerJA , KuppermannBD , BlumenkranzMS , WilliamsGA , WeinbergDV , ChouC , et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Archives of Ophthalmology2010;128(3):289-96. HallerJA , WeinbergD , ChouC , IpM , DavisM , WhitcupSM . Correlation of macular thickness and visual acuity in patients with persistent macular edema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5908. HallerJA , WeinbergDV , ChouC , lpMS , DavisMD , WhitcupSM . Correlation of visual acuity and macular thickness as measured by OCT in patients with persistent macular edema. In: American Academy of Ophthalmology. 2006:297. KuppermannBD , BlumenkranzMS , HallerJA , WilliamsGA , WeinbergDV , ChouC , et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Archives of Ophthalmology2007;125(3):309-17. KuppermannBD , BlumenkranzMS , HallerJA , WilliamsGA , Posurdex Study Group. An intravitreous dexamethasone bioerodible drug delivery system for the treatment of persistent diabetic macular edema. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4289. KuppermannBD , ChouC , WeinbergDV , WhitcupDV , HallerJA , BlumenkranzMS . Response to a sustained-release dexamethasone posterior-segment drug delivery system for different patterns of diabetic macular edema. In: American Academy of Ophthalmology. 2005:249. KuppermannBD , ChouC , WeinbergDV , WhitcupSM , HallerJA , BlumenkranzMS , et al. Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Archives of Ophthalmology2010;128(5):642-3. KuppermannBD , HallerJA , WilliamsGA , BlumenkranzMS . A randomized controlled trial to assess the safety and efficacy of a dexamethasone implant for diabetic macular edema. In: American Academy of Ophthalmology. 2003:150. WilliamsGA , HallerJA , KuppermannBD , BlumenkranzMS , WeinbergDV , ChouC , et al. Evaluation of an intravitreous dexamethasone drug delivery system in patients with persistent diabetic macular edema. In: American Academy of Ophthalmology. 2006:192. ">Kuppermann 2007</a>; <a href="./references#CD005656-bbs2-0070" title="Nancy Groves, Reviewed by PearsonPA . Steroids implant reduces retinal thickness, improves vision. Ophthalmology Times 15 November 2004:24-6. PearsonPA , BakerCW , EliottD , IpMS , MoreseLS , CallananDG . Fluocinolone acetonide intravitreal implant for diabetic macular edema: 2 year results. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 4673. PearsonPA , BakerCW , EliottD , IpMS , MoreseLS , CallananDG . Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema. In: American Academy of Ophthalmology Annual Meeting. 2002. PearsonPA , EliottD , BakerCW , IpMS , MoreseLS , CallananDG . Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema. In: Association for Research in Vision and Ophthalmology Annual Meeting. 2003. ">Pearson 2002</a>; <a href="./references#CD005656-bbs2-0071" title="Nancy Groves, Reviewed by PearsonPA . Patients with DME have response to fluocinolone acetonide intravitreal implant in study outcomes. Ophthalmology Times 1 August 2006:38. PearsonPA , BevyB , Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. In: Association for Research in Vision and Ophthalmology Annual Meeting. 2005. PearsonPA , ComstockTL , IpM , CallananD , MorseLS , AshtonP , et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology2011;118(8):1580-7. PearsonPA , LevyB , ComstockT , Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5442. ">Pearson 2011</a>). <a href="./references#CD005656-bbs2-0071" title="Nancy Groves, Reviewed by PearsonPA . Patients with DME have response to fluocinolone acetonide intravitreal implant in study outcomes. Ophthalmology Times 1 August 2006:38. PearsonPA , BevyB , Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. In: Association for Research in Vision and Ophthalmology Annual Meeting. 2005. PearsonPA , ComstockTL , IpM , CallananD , MorseLS , AshtonP , et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology2011;118(8):1580-7. PearsonPA , LevyB , ComstockT , Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5442. ">Pearson 2011</a> included two reports, which we considered possible duplicates. Of the seven trials previously included, only two were eligible for this update because we modified the eligibility criteria (<a href="#CD005656-fig-0001">Figure 1</a>) (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). </p> <div class="figure" id="CD005656-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005656-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The updated searches in May 2019 yielded 2441 additional unique records (<a href="#CD005656-fig-0001">Figure 1</a>). We excluded 2304 records based on title and abstract and retrieved the full‐text reports for 137 records. We included 43 reports of 9 trials and excluded 91 reports of 69 trials (see <a href="./references#CD005656-sec-0112" title="">Characteristics of excluded studies</a> table). In total, we included 10 trials (2 trials from the original review and 8 trials from the updated searches) (see <a href="./references#CD005656-sec-0111" title="">Characteristics of included studies</a> table). We identified two ongoing studies and one study awaiting classification that potentially met the inclusion criteria; we will assess these studies when data become available (see <a href="./references#CD005656-sec-0114" title="">Characteristics of ongoing studies</a> and <a href="./references#CD005656-sec-0113" title="">Characteristics of studies awaiting classification</a>). </p> <p>Among excluded studies, <a href="./references#CD005656-bbs2-0070" title="Nancy Groves, Reviewed by PearsonPA . Steroids implant reduces retinal thickness, improves vision. Ophthalmology Times 15 November 2004:24-6. PearsonPA , BakerCW , EliottD , IpMS , MoreseLS , CallananDG . Fluocinolone acetonide intravitreal implant for diabetic macular edema: 2 year results. Investigative Ophthalmology and Visual Science2004;45(13):ARVO E-abstract 4673. PearsonPA , BakerCW , EliottD , IpMS , MoreseLS , CallananDG . Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema. In: American Academy of Ophthalmology Annual Meeting. 2002. PearsonPA , EliottD , BakerCW , IpMS , MoreseLS , CallananDG . Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema. In: Association for Research in Vision and Ophthalmology Annual Meeting. 2003. ">Pearson 2002</a> and <a href="./references#CD005656-bbs2-0071" title="Nancy Groves, Reviewed by PearsonPA . Patients with DME have response to fluocinolone acetonide intravitreal implant in study outcomes. Ophthalmology Times 1 August 2006:38. PearsonPA , BevyB , Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. In: Association for Research in Vision and Ophthalmology Annual Meeting. 2005. PearsonPA , ComstockTL , IpM , CallananD , MorseLS , AshtonP , et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology2011;118(8):1580-7. PearsonPA , LevyB , ComstockT , Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5442. ">Pearson 2011</a> randomized participants with DME to intravitreal fluocinolone 0.59 mg (Retisert implant) or standard of care. We did not include these studies because this type of fluocinolone implant has not been approved for treatment of DME. </p> <p>The top up search identified 216 records. We classified a study with 30 participants (<a href="./references#CD005656-bbs2-0088" title="McKeeKM , HongG , GordonGM , PiereamiciDJ . Dexamethasone Intravitreal Implant versus Intravitreal Anti-VEGF for the Treatment of Persistent Diabetic Macular Edema, Twelve Month Study Analysis (DIME Study). In: Investigative Ophthalmology &amp; Visual Science July 2019, Vol.60, 2610. June 2019. ">McKee 2019</a>), presented in an abstract, as awaiting classification (<a href="./references#CD005656-sec-0113" title="">Characteristics of studies awaiting classification</a>). We identified one ongoing study and one report of an existing trial (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>) </p> </section> <section id="CD005656-sec-0047"> <h4 class="title">Included studies</h4> <section id="CD005656-sec-0048"> <h5 class="title">Types of participants</h5> <p>We included 10 trials from 26 countries (Austria, Australia, Belgium, Brazil, Canada, Colombia, the Czech Republic, Denmark, France, Germany, Hungary, India, Israel, Italy, the Netherlands, New Zealand, the Philippines, Poland, Portugal, Singapore, South Africa, South Korea, Spain, Taiwan, the United Kingdom, and the United States) with a total of 4505 DME eyes. The trials varied in size, with eight trials enrolling 30 to 363 DME eyes, and the largest three trials enrolling 840, 956, and 1048 DME eyes. Participants were male and female adults. The duration of the trials ranged from 9 months (we aimed to include trials at 12 months but accepted studies with follow‐up within ±3 months) to 36 months. </p> <p>We found clinical heterogeneity in the inclusion/exclusion criteria of trials. Five trials included participants with persistent DME despite at least one prior treatment with laser photocoagulation (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Four trials excluded individuals who had undergone prior laser photocoagulation or intraocular injections for treatment of DME (<a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>). <a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a> included participants with cystoid macular edema (CME), generally considered to be a more severe and more chronic form of edema, as well as participants with DME, branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). </p> <p>Regarding the visual function and retina morphology of eligible participants, nine trials required the baseline VA to be 20/25 or worse in the study eye for inclusion (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Four trials required the central macular thickness to be at least 250 microns on time domain optical coherence tomography (TD‐OCT) and at least 300 microns on spectral domain optical coherence tomography (SD‐OCT) (<a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>). Nine trials excluded individuals who had a history of glaucoma, uncontrolled ocular hypertension, or corticosteroid‐induced ocular hypertension (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). </p> <p>Regarding participants' characteristics, seven trials were comparable with regard to the duration of diabetes (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>). Six trials were comparable with regard to the duration of DME (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>). Ten trials were comparable with regard to baseline VA (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Ten trials were comparable with regard to baseline retinal thickness (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>), and nine trials were comparable with regard to baseline IOP (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). </p> </section> <section id="CD005656-sec-0049"> <h5 class="title">Types of intervention</h5> <p>Two types of intravitreal steroids therapies were evaluated in the included trials: intravitreal steroid injection and intravitreal steroid implantation. Of the six intravitreal injection trials, two trials compared intravitreal triamcinolone injection with intravitreal antiVEGF therapy (<a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>). <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a> compared intravitreal triamcinolone injection with sham procedure or no treatment, and three trials compared intravitreal triamcinolone injection with laser photocoagulation (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>). All seven intravitreal injection trials used a 4.0 mg dose of intravitreal triamcinolone injection, except <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>, which used a 8.0 mg dose, and <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>, which used a 2.0 mg dose. The preoperative preparation and surgical techniques of intravitreal triamcinolone injection were comparable between trials. Of the four intravitreal steroid implantation trials (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>), <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a> compared two different dosages of fluocinolone implant with sham injection; we extracted data on the commercially available dose. Of the remaining three intravitreal steroid implantation trials, <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a> compared two different dosages of dexamethasone with a sham procedure and we extracted data on the commercially available dose. <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> and <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a> compared a 0.7 mg dose of dexamethasone to intravitreal antiVEGF therapy. </p> </section> <section id="CD005656-sec-0050"> <h5 class="title">Primary outcome</h5> <p>All trials measured and reported VA. All trials assessed VA by ETDRS chart, the most standardized method. Ways to aggregate VA data varied across trials. Four trials reported final values (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>); six trials reported the degree of change relative to pre‐injection level (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>); seven trials reported three or more lines improvement (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>); and three trials reported one or more lines improvement (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>). </p> </section> <section id="CD005656-sec-0051"> <h5 class="title">Secondary outcomes</h5> <p>Retinal thickness data were reported and discussed in all 10 trials (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Of the 10 trials, six trials reported final values (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>), and four trials reported the degree of change relative to pre‐injection level (<a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Two trials reported on fluorescein leakage (<a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>). </p> <p>None of the trials reported quality of life or economic data.</p> </section> </section> <section id="CD005656-sec-0052"> <h4 class="title">Excluded studies</h4> <p>For further details, see <a href="./references#CD005656-sec-0112" title="">Characteristics of excluded studies</a>. </p> <p>To summarize, we excluded 20 studies due to ineligible intervention or comparison (e.g. intravitreal steroids in combination therapy, vitrectomy), 29 because follow‐up was shorter than 9 months, 19 due to ineligible study design (e.g. non‐randomized or non‐comparative), five for other reasons (e.g. only abstract available), and two because a type of fluocinolone implant was used that is approved for uveitis but not for DME (Retisert implant). </p> </section> </section> <section id="CD005656-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias of the included studies is shown in <a href="#CD005656-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD005656-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005656-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005656-sec-0054"> <h4 class="title">Allocation</h4> <p>Reports from seven trials described methods of random sequence generation that we considered to be at low risk of bias: one trial used stratified block randomization (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>); three trials used block randomization (<a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>); and three trials only reported using a computer‐randomized method (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>). We assessed the remaining three trials, which did not describe the methods of generating the allocation sequence, as at unclear risk of bias (<a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>). </p> <p>Reports from five trials described methods of allocation concealment that we considered to be at low risk of bias: two used sealed and opaque envelopes(<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>); one used central allocation through computer (<a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>); and two used an automated interactive voice response (<a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>). We assessed the remaining five randomized controlled trials, which did not describe the methods of allocation concealment in sufficient detail, as at unclear risk of bias (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>). </p> </section> <section id="CD005656-sec-0055"> <h4 class="title">Blinding</h4> <p><a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a> reported masking of participants, study personnel, and outcome assessors. <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>, <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>, and <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a> reported that outcome assessors were masked (low risk of bias); however, they did not report whether study participants were masked. <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a> and <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a> masked outcome assessors but did not mask participants or study personnel. The remaining four trials provided insufficient information on masking and were therefore assessed as at unclear risk of bias (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>). </p> </section> <section id="CD005656-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We considered four trials as at low risk of bias for incomplete outcome data because there were less than 10% of missing outcome data, and losses to follow‐up and reasons for losses to follow‐up were balanced between group (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>). We considered six trials as at high risk of bias for incomplete outcome data: four trials had 16% to 22% participants with missing outcome data (<a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>), and in two trials proportions of loss to follow‐up were more than 25% (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>). </p> <p>Eight trials performed intention‐to‐treat analysis. Of these eight trials, four used the 'last observation carried forward' (LOCF) method to impute missing data and were rated as at high risk of bias (<a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Two other trials also used the LOCF method, which is suboptimal, but were rated as at low risk of bias since they had few and balanced losses to follow‐up (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>). We rated <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a> as at low risk of bias as they used observed data in the analyses of our outcomes of interest, and <a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a> as at unclear risk of bias since they did not report the method used to impute data. We considered <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a> and <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>, which conducted a complete‐case analysis, as at high risk of bias. </p> </section> <section id="CD005656-sec-0057"> <h4 class="title">Selective reporting</h4> <p>We considered eight trials as at low risk of reporting bias because the outcomes described in the results matched those in the trial registrations (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>; <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>; <a href="./references#CD005656-bbs2-0007" title="LimJW , LeeHK , ShinMC . Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica2012;227(2):100-6. ">Lim 2012</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>; <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). We considered two trials in which a trial registration or protocol was unavailable as at unclear risk of bias (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0009" title="HykinP , OckrimZ , FalkS , SivaprasadS , GregorZ , TufailA . A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema. In: The Macula Society. 2006:174. OckrimZK , SenswathiS , FalkS , OjedaF , SchadtM , GregorZ , et al. A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema. Investigative Ophthalmology and Visual Science2006;47(13):ARVO E-abstract 5438. OckrimZK , SivaprasadS , FalkS , RoghaniS , BunceC , GregorZ , et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. British Journal of Ophthalmology2008;92(6):795-9. SivaprasadS , OckrimZ , MassaoutisP , IkejiF , HykinPG , GregorZJ . Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Retina (Philadelphia, Pa.)2008;28(10):1435-42. ">Ockrim 2008</a>). </p> </section> </section> <section id="CD005656-sec-0058"> <h3 class="title" id="CD005656-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD005656-tbl-0001"><b>Summary of findings 1</b> Intravitreal dexamethasone implant 0.7 mg compared to sham for macular edema in diabetes</a>; <a href="./full#CD005656-tbl-0002"><b>Summary of findings 2</b> Intravitreal dexamethasone implant 0.7 mg compared to intravitreal antiVEGF for macular edema in diabetes</a>; <a href="./full#CD005656-tbl-0003"><b>Summary of findings 3</b> Intravitreal fluocinolone acetonide implant 0.19 mg compared to sham for macular edema in diabetes</a>; <a href="./full#CD005656-tbl-0004"><b>Summary of findings 4</b> Intravitreal triamcinolone acetonide injection 4 mg compared to sham for macular edema in diabetes</a>; <a href="./full#CD005656-tbl-0005"><b>Summary of findings 5</b> Intravitreal triamcinolone acetonide injection 4 mg compared to macular laser for macular edema in diabetes</a>; <a href="./full#CD005656-tbl-0006"><b>Summary of findings 6</b> Intravitreal triamcinolone acetonide injection 4 mg compared to antiVEGF for macular edema in diabetes</a> </p> <section id="CD005656-sec-0059"> <h4 class="title">Intravitreal dexamethasone implant versus sham</h4> <p><a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a> compared dexamethasone implant 0.7 mg and 0.35 mg with sham. We extracted data for the 0.7 mg group (as this is the commercially available dose) versus sham in 701 participants (<a href="./full#CD005656-tbl-0001">summary of findings Table 1</a>). We reported results on efficacy at 12 to 36 months and safety data at 36 months. Many participants were lost to follow‐up at 36 months, thus the certainty of evidence was downgraded for risk of bias at this time point. </p> <section id="CD005656-sec-0060"> <h5 class="title">Visual acuity</h5> <p>Our primary time frame was at 12 months, when intravitreal dexamethasone led to a better improvement of VA than sham (mean difference (MD) −0.08 logMAR, 95% confidence interval (CI) −0.12 to −0.05 logMAR; trials = 1; participants = 701; moderate‐certainty evidence, downgraded for risk of bias). There was no evidence of a difference at 24 months (MD 0.00 logMAR, 95% CI −0.04 to 0.05 logMAR; trial = 1; participants = 701; moderate‐certainty evidence, downgraded for risk of bias), and evidence of a small difference at 36 months (MD −0.05, 95% CI −0.09 to 0.00; trials = 1; participants = 701; low‐certainty evidence, downgraded for risk of bias and imprecision) (<a href="./references#CD005656-fig-0009" title="">Analysis 1.1</a>; <a href="#CD005656-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD005656-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.1 Change in visual acuity [logMAR]." data-id="CD005656-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.1 Change in visual acuity [logMAR]. </p> </div> </div> </div> <p>Regarding the improvement of three or more lines of VA at 12 months, although the risk ratio (RR) favored intravitreal dexamethasone, the 95% CI included null (RR 1.39, 95% CI 0.91 to 2.12; trials = 1; participants = 701; moderate‐certainty evidence, downgraded for risk of bias). Intravitreal dexamethasone was more effective than sham at 24 months (RR 1.54, 95% CI 1.04 to 2.26; trial = 1; participants = 701; low‐certainty evidence, downgraded for risk of bias and imprecision) and 36 months (RR 1.83, 95% CI 1.29 to 2.58; trial = 1; participants = 701; moderate‐certainty evidence, downgraded for risk of bias) (<a href="./references#CD005656-fig-0010" title="">Analysis 1.2</a>; <a href="#CD005656-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD005656-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.2 Gain of three or more lines visual acuity." data-id="CD005656-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.2 Gain of three or more lines visual acuity. </p> </div> </div> </div> </section> <section id="CD005656-sec-0061"> <h5 class="title">Central retinal thickness</h5> <p>No data were available at 12 and 24 months. There was a greater and clinically important reduction of retinal thickness with intravitreal dexamethasone at 36 months compared to sham (−81.00 µm, 95% CI −98.64 to −63.36 µm; moderate‐certainty evidence, downgraded for risk of bias) (<a href="./references#CD005656-fig-0011" title="">Analysis 1.3</a>). </p> </section> <section id="CD005656-sec-0062"> <h5 class="title">Adverse events</h5> <p>Compared to sham, at 36 months intravitreal dexamethasone increased the risk of cataract progression by about 4 times (RR 3.89, 95% CI 2.75 to 5.50; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0012" title="">Analysis 1.4</a>). Dexamethasone also increased all IOP‐related events: IOP increase (RR 8.99, 95% CI 5.05 to 16.03) and use of IOP‐lowering medications (RR 4.54, 95% CI 3.19 to 6.46; moderate‐certainty evidence for both outcomes, downgraded for risk of bias; <a href="./references#CD005656-fig-0013" title="">Analysis 1.5</a>; <a href="./references#CD005656-fig-0014" title="">Analysis 1.6</a>); about 4 in 10 participants treated with dexamethasone needed IOP‐lowering medications. The need for glaucoma surgery was increased but imprecisely estimated since only 1 to 2 out of 100 participants needed surgery for glaucoma (RR 5.04, 95% CI 0.59 to 42.95; low‐certainty evidence, downgraded for risk of bias and imprecision; <a href="./references#CD005656-fig-0015" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD005656-sec-0063"> <h4 class="title">Intravitreal dexamethasone implant versus intravitreal antiVEGF</h4> <p>Two trials (434 participants, 451 eyes) compared intravitreal dexamethasone versus intravitreal antiVEGF (<a href="./full#CD005656-tbl-0002">summary of findings Table 2</a>) (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>). </p> <section id="CD005656-sec-0064"> <h5 class="title">Visual acuity</h5> <p>At 12 months, VA improvement was slightly less by 0.07 logMAR (95% CI 0.04 to 0.09 logMAR; trials = 2; eyes = 451; I<sup>2</sup> = 0%; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0016" title="">Analysis 2.1</a>; <a href="#CD005656-fig-0005">Figure 5</a>) with dexamethasone compared to antiVEGF. </p> <div class="figure" id="CD005656-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.1 Change in visual acuity [logMAR]." data-id="CD005656-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.1 Change in visual acuity [logMAR]. </p> </div> </div> </div> <p>The RR of gain of three or more lines of VA was inconsistent between trials, with <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> (88 eyes) finding no evidence of a difference between dexamethasone and bevacizumab at 12 months (RR 0.99, 95% CI 0.70 to 1.40), and <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a> (432 participants) finding that the chances of vision gain were half with dexamethasone compared with ranibizumab (RR 0.50, 95% CI 0.32 to 0.79) (overall low‐certainty evidence, downgraded for risk of bias and inconsistency) (<a href="./references#CD005656-fig-0017" title="">Analysis 2.2</a>; <a href="#CD005656-fig-0006">Figure 6</a>). At 24 months, <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> found no evidence of a difference in gaining three or more lines of vision (RR 0.96, 95% CI 0.60 to 1.54; low‐certainty evidence, downgraded for risk of bias and imprecision). </p> <div class="figure" id="CD005656-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.2 Gain of three or more lines visual acuity." data-id="CD005656-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.2 Gain of three or more lines visual acuity. </p> </div> </div> </div> </section> <section id="CD005656-sec-0065"> <h5 class="title">Central retinal thickness</h5> <p>The mean change in retinal thickness may be greater with intravitreal dexamethasone than bevacizumab at 12 months, with inconsistent results from two trials. Both trials slightly favored dexamethasone (MD −21.09 µm, 95% CI −41.90 to −0.28 µm; trials = 2; eyes = 451; I<sup>2</sup> = 76%; low‐certainty evidence, downgraded for risk of bias and inconsistency; <a href="./references#CD005656-fig-0018" title="">Analysis 2.3</a>); however, the bevacizumab group in <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> seemed to do less well compared to the bevacizumab group in <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>. <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> (50 eyes) also favored dexamethasone compared to bevacizumab at 24 months (MD −109.00 µm, 95% CI −171.37 to −46.63 µm; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0018" title="">Analysis 2.3</a>). </p> </section> <section id="CD005656-sec-0066"> <h5 class="title">Adverse events</h5> <p>We planned to report adverse events at the longest available follow‐up, which was 12 months for <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> and 24 months for <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>. </p> <p>Compared to antiVEGF, intravitreal dexamethasone increased the risk of cataract progression by about 4 times (RR 4.23, 95% CI 2.36 to 7.59; participants = 335; trials = 2; I<sup>2</sup> = 0%; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0019" title="">Analysis 2.4</a>). Dexamethasone also increased all IOP‐related events: IOP increase (RR 2.93, 95% CI 1.53 to 5.50; participants = 451; trials = 2; I<sup>2</sup> = 0%; <a href="./references#CD005656-fig-0020" title="">Analysis 2.5</a>) and use of IOP‐lowering medications (RR 4.76, 95% CI 2.84 to 7.99; participants = 363; trials = 1; <a href="./references#CD005656-fig-0021" title="">Analysis 2.6</a>). As found above, about 4 or 5 out of 10 participants treated with dexamethasone needed IOP‐lowering medications. The need for glaucoma surgery seemed to be increased, but there was no evidence of a difference between dexamethasone and sham since this was imprecisely estimated: only 1 to 2 out of 100 participants needed surgery for glaucoma (RR 3.02, 95% CI 0.12 to 73.56; very low‐certainty evidence, downgraded one level for risk of bias and two levels for imprecision; <a href="./references#CD005656-fig-0022" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD005656-sec-0067"> <h4 class="title">Intravitreal fluocinolone implant versus sham</h4> <p>One trial (560 participants) evaluated fluocinolone implant (Iluvien) versus sham (<a href="./full#CD005656-tbl-0003">summary of findings Table 3</a>) (<a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>). </p> <section id="CD005656-sec-0068"> <h5 class="title">Visual acuity</h5> <p>Visual acuity improved slightly more with fluocinolone implant at 12 and 24 months (MD −0.04 logMAR, 95% CI −0.06 to −0.01 logMAR and MD −0.06 logMAR, 95% CI −0.08 to −0.03 logMAR, respectively; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0023" title="">Analysis 3.1</a>; <a href="#CD005656-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD005656-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.1 Change in visual acuity." data-id="CD005656-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.1 Change in visual acuity. </p> </div> </div> </div> <p>At 12 months, an improvement in VA of three or more lines was more common with fluocinolone implant than sham (RR 1.79, 95% CI 1.16 to 2.78; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0024" title="">Analysis 3.2</a>). </p> <p>Data at 24 months confirmed the estimates obtained at 12 months (three or more lines improvement in VA: RR 1.76, 95% CI 1.22 to 2.53; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0024" title="">Analysis 3.2</a>; <a href="#CD005656-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD005656-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.2 Gain of three or more lines visual acuity." data-id="CD005656-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.2 Gain of three or more lines visual acuity. </p> </div> </div> </div> </section> <section id="CD005656-sec-0069"> <h5 class="title">Central retinal thickness</h5> <p>The reduction in central retinal thickness was greater with fluocinolone compared with sham both at 12 months (MD −76 µm, 95% CI −94.31 to −57.69 µm) and 24 months (MD −59 µm, 95% CI −77.31 to −40.69 µm) (moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0025" title="">Analysis 3.3</a>). </p> </section> <section id="CD005656-sec-0070"> <h5 class="title">Adverse events</h5> <p>We planned to report adverse events at the longest available follow‐up, which was 24 months in <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>. </p> <p>One‐half of phakic participants assigned to sham needed cataract surgery in <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>, meaning that the risk ratio could not exceed two for this analysis. Compared to sham, intravitreal fluocinolone increased the risk of cataract progression by about 60% (RR 1.63, 95% CI 1.35 to 1.97; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0026" title="">Analysis 3.4</a>). Fluocinolone also increased all IOP‐related events: IOP increase (RR 3.35, 95% CI 2.22 to 5.06; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0027" title="">Analysis 3.5</a>) and use of IOP‐lowering medications (RR 2.72, 95% CI 1.87 to 3.98; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0028" title="">Analysis 3.6</a>). About 2 to 3 out of 10 participants treated with fluocinolone needed IOP‐lowering medications. The need for glaucoma surgery increased with fluocinolone but was imprecisely estimated, as about 5 in 100 participants needed surgery for glaucoma (RR 9.54, 95% CI 1.28 to 70.93; low‐certainty evidence, downgraded for risk of bias and imprecision; <a href="./references#CD005656-fig-0029" title="">Analysis 3.7</a>). </p> </section> </section> <section id="CD005656-sec-0071"> <h4 class="title">Intravitreal triamcinolone injection versus sham</h4> <p>One trial (69 eyes of 43 participants) compared intravitreal triamcinolone injection with a sham procedure (<a href="./full#CD005656-tbl-0004">summary of findings Table 4</a>) (<a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a>). Data were available only at 24 months. </p> <section id="CD005656-sec-0072"> <h5 class="title">Visual acuity</h5> <p><a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a> (69 eyes) found the MD in VA of −0.11 logMAR (95% CI −0.20 to −0.03 logMAR; low‐certainty evidence, downgraded for risk of bias and imprecision; <a href="./references#CD005656-fig-0030" title="">Analysis 4.1</a>) in favor of intravitreal triamcinolone injection at 24 months. The RR of gain of three or more lines was imprecisely estimated (RR 4.12, 95% CI 0.48 to 34.99; very low‐certainty evidence, downgraded for risk of bias and two levels for imprecision; <a href="./references#CD005656-fig-0031" title="">Analysis 4.2</a>). </p> </section> <section id="CD005656-sec-0073"> <h5 class="title">Central retinal thickness</h5> <p>Comparing intravitreal triamcinolone injection with sham at 24 months, <a href="./references#CD005656-bbs2-0010" title="GilliesM . Diabetic macular edema. Ophthalmology2009;116(3):595-7. GilliesMC , IslamFM , LarssonJ , PasadhikaS , PasadhikaS , GastonC , et al. Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. Clinical and Experimental Ophthalmology2010;38(6):605-12. GilliesMC , SimpsonJM , GastonC , HuntG , AliH , ZhuM , et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology2009;116(11):2182-7. GilliesMC , SimpsonJM , ZhuM , HuntG , AliH , GastonC . Intravitreal triamcinolone. Ophthalmology2009;116(3):591. GilliesMC , SutterFK , SimpsonJM , LarssonJ , AliH , ZhuM . Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology2006;113(9):1533-8. GilliesMC , SutterFKP . Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 3219. GilliesMC , ZhuM , SimpsonJM , SutterFKP . A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment—2-year results. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 4672. GilliesMC . Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension. Investigative Ophthalmology and Visual Science2008;49(13):ARVO E-abstract 1565. LarssonJ , KifleyA , ZhuM , WangJJ , MitchellP , SutterFK , et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmologica2009;87(3):275-80. LarssonJ , WangJ , KifleyA , MitchellP , SutterF , ZhuM , et al. Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy—a pilot, randomized controlled clinical trial. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1444. SutterFK , SimpsonJM , GilliesMC . Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004;111(11):2044-9. SutterFKP , GilliesMC . Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO. Investigative Ophthalmology and Visual Science2003;44(13):ARVO E-abstract 4003. WickremasingheSS , RogersSL , GilliesMC , ZhuM , WongTY . Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Investigative Ophthalmology and Visual Science2008;49(11):4707-11. ZhuM , LarssonJ , JamalH , GilliesM . Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone. Investigative Ophthalmology and Visual Science2005;46(13):ARVO E-abstract 1439. ">Sutter 2004</a> (69 eyes) found the MD in retinal thickness was −59.0 µm (95% CI −103.5 to −14.5 µm; low‐certainty evidence, downgraded for risk of bias and imprecision; <a href="./references#CD005656-fig-0032" title="">Analysis 4.3</a>), in favor of intravitreal triamcinolone injection. </p> </section> <section id="CD005656-sec-0074"> <h5 class="title">Adverse events</h5> <p>As for other intravitreal steroids, the risk of cataract progression and IOP‐related events was increased, but this was imprecisely estimated due to the small sample size of the study: cataract progression RR 3.00 (95% CI 0.97 to 9.30); IOP increase RR 10.3 (95% CI 1.39 to 76.1); use of IOP‐lowering medications RR 21.6 (95% CI 1.32 to 354.72). No participant needed glaucoma surgery in this study. All evidence was of low‐ or very low‐certainty due to risk of bias and imprecision. </p> </section> </section> <section id="CD005656-sec-0075"> <h4 class="title">Intravitreal triamcinolone injection versus laser photocoagulation</h4> <p>Two trials investigated the effect of intravitreal triamcinolone injection versus laser photocoagulation (<a href="./full#CD005656-tbl-0005">summary of findings Table 5</a>) (<a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a>; <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>). <a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a> included 63 eyes of 56 participants randomized to triamcinolone 4 mg, macular laser, or combination therapy (31 eyes included in our analyses). <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a> included 840 eyes of 693 participants randomized to triamcinolone 1 mg or 4 mg, or to macular laser, from which we extracted data on 584 eyes assigned to either the commercial dose of triamcinolone (4 mg; 256 eyes) or macular laser (330 eyes). </p> <section id="CD005656-sec-0076"> <h5 class="title">Visual acuity</h5> <p>A small study, <a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a> (31 eyes) found a benefit with intravitreal triamcinolone injection compared with laser photocoagulation at 9 months (MD −0.18 logMAR, 95% CI −0.29 to −0.07 logMAR), but a large, multicenter study (<a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>, 584 eyes) found no evidence of benefit at 12 months (MD 0.02 logMAR, 95% CI −0.03 to 0.07 logMAR; overall very low‐certainty evidence, downgraded one level for risk of bias and two levels for inconsistency; <a href="./references#CD005656-fig-0037" title="">Analysis 5.1</a>). </p> <p>In <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a>, the proportion of participants gaining three or more VA lines was similar for the triamcinolone group compared with the laser group at 12 months (RR 0.85, 95% CI 0.55 to 1.30) and 24 months (RR 0.95, 95% CI 0.66 to 1.35) (low‐certainty evidence for both outcomes, downgraded for risk of bias and imprecision; <a href="./references#CD005656-fig-0038" title="">Analysis 5.2</a>). </p> </section> <section id="CD005656-sec-0077"> <h5 class="title">Central retinal thickness</h5> <p>Data on central retinal thickness (<a href="./references#CD005656-fig-0039" title="">Analysis 5.3</a>) followed those on visual function, with <a href="./references#CD005656-bbs2-0001" title="AvitabileT , LongoA , ReibaldiA . Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology2005;140(4):695-702. ">Avitabile 2005</a> finding a greater reduction with triamcinolone at 9 months, which was imprecisely estimated and included no difference (31 eyes; MD −83.00 micron, 95% CI −171.60 to −5.60 micron), and <a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a> finding no evidence of a difference at 12 months (554 eyes; MD 5.00, 95% CI −18.76 to 28.76) (overall very low‐certainty evidence, downgraded one level for risk of bias and two levels for inconsistency). </p> <p><a href="./references#CD005656-bbs2-0004" title="AielloLP , EdwardsAR , BeckRW , BresslerNM , DavisMD , FerrisF , et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology2010;117(5):946-53. BresslerNM , EdwardsAR , BeckRW , FlaxelCJ , GlassmanAR , IpMS , et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Archives of Ophthalmology2009;127(12):1566-71. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology2008;115(9):1447-9. Diabetic Retinopathy Clinical Research Network (DRCRnet), BeckRW , EdwardsAR , AielloLP , BresslerNM , FerrisF , GlassmanAR , et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology2009;127(3):245-51. IpMS , BresslerSB , AntoszykAN , FlaxelCJ , KimJE , FriedmanSM , et al. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina2008;28(7):919-30. IpMS . A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics. Investigative Ophthalmology and Visual Science2008:ARVO E-abstract 3468. LauerAK , BresslerNM , EdwardsAR , Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. Archives of Ophthalmology2011;129(8):1097-9. WykoffCC , HariprasadSM . DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema. Ophthalmic Surgery Lasers and Imaging Retina2016;47(4):308-12. ">DRCR.net 2008</a> found better results with laser at 24 months (MD 62.00, 95% CI 33.16 to 90.84; participants = 454; trials = 1; low‐certainty evidence, downgraded for risk of bias and imprecision). </p> </section> <section id="CD005656-sec-0078"> <h5 class="title">Adverse events</h5> <p>At the longest‐available follow‐up (9 to 24 months), the risk of cataract progression increased by about 3 times (RR 2.68, 95% CI 2.21 to 3.24; moderate‐certainty evidence, downgraded for risk of bias; <a href="./references#CD005656-fig-0040" title="">Analysis 5.4</a>). IOP‐related events also increased: IOP increase (RR 9.62, 95% CI 5.44 to 17.03; participants = 627; trials = 2; I<sup>2</sup> = 0%; <a href="./references#CD005656-fig-0041" title="">Analysis 5.5</a>); use of IOP‐lowering medications (RR 3.92, 95% CI 2.59 to 5.96; participants = 627; trials = 2; I<sup>2</sup> = 0%; <a href="./references#CD005656-fig-0042" title="">Analysis 5.6</a>) (moderate‐certainty evidence for both outcomes, downgraded for risk of bias). About 1 in 3 participants needed IOP‐lowering medication. The need for glaucoma surgery increased (RR 11.68, 95% CI 0.63 to 216) (<a href="./references#CD005656-fig-0043" title="">Analysis 5.7</a>), but this evidence was of low‐certainty due to risk of bias and imprecision. </p> </section> </section> <section id="CD005656-sec-0079"> <h4 class="title">Intravitreal triamcinolone injection versus intravitreal antiVEGF</h4> <p>One trial (30 participants assigned to triamcinolone, 15 to bevacizumab, and 15 to ranibizumab) compared intravitreal triamcinolone injection with intravitreal bevacizumab or ranibizumab (<a href="./full#CD005656-tbl-0006">summary of findings Table 6</a>) (<a href="./references#CD005656-bbs2-0006" title="DeakGG , LammerJ , PragerS , MylonasG , BolzM , Schmidt-ErfurthU . Refractive changes after pharmacologic resolution of diabetic macular edema. Ophthalmology2014;121:1054-8. KriechbaumK , PragerS , MylonasG , ScholdaC , RainerG , FunkM , et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye2014;28(1):9-15. PragerSG , LammerJ , MitschC , HafnerJ , PempB , ScholdaC , et al. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. Acta Ophthalmologica2018;96:e195-200. ">Kriechbaum 2014</a>). The authors reported results in two separate publications, one for bevacizumab and one for ranibizumab; we used the data available in the manuscripts as well as in the trial registries. </p> <section id="CD005656-sec-0080"> <h5 class="title">Visual acuity</h5> <p>At 12 months, mean VA improved less with intravitreal triamcinolone injection compared with bevacizumab or ranibizumab (MD 0.18 logMAR, 95% CI 0.10 to 0.26 logMAR; trials = 1; participants = 60; low‐certainty evidence, downgraded for risk of bias and imprecision; <a href="./references#CD005656-fig-0044" title="">Analysis 6.1</a>). The proportion of patients improving by 3 or more VA lines was not reported. </p> </section> <section id="CD005656-sec-0081"> <h5 class="title">Central retinal thickness</h5> <p>At 12 months, there was an inconsistent reduction in retinal thickness with intravitreal triamcinolone injection versus bevacizumab compared with ranibizumab, and we could not draw any conclusions (<a href="./references#CD005656-fig-0045" title="">Analysis 6.2</a>). </p> </section> <section id="CD005656-sec-0082"> <h5 class="title">Adverse events</h5> <p>No data were available for cataract progression. The authors stated that mean IOP did not differ between triamcinolone and bevacizumab groups, but provided no data on the IOP‐related event we aimed to include (i.e. need for additional medications or surgery). </p> </section> </section> <section id="CD005656-sec-0083"> <h4 class="title">Subgroup analyses in pseudophakic participants</h4> <p>The larger studies reported data on the subgroup of pseudophakic participants, who do not suffer from visual loss due to cataract progression. We summarized these data narratively, since no comparative data were available for both phakic and pseudophakic participants, except for in one study. </p> <p><a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a> reported that the difference between fluocinolone and sham was gradually reduced to about 1 ETDRS letter (0.02 logMAR) at 18 months, but increased after cataract surgery in several participants. On the other hand, this difference continued to increase during follow‐up in 223 pseudophakic participants, with a maximum final difference of about 6 ETDRS letters (0.12 logMAR). A similar pattern was recorded in <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a> comparing intravitreal dexamethasone with sham in 187 pseudophakic participants. </p> <p><a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a> reported a similar change in VA overall versus in pseudophakic participants at 12 months. In the pseudophakic subgroup, VA improved by 4.6 letters (0.092 logMAR) with dexamethasone and 6.6 letters (−0.132 logMAR) with ranibizumab (P &lt; 0.029). <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a> reported no statistically significant difference in VA change between pseudophakic eyes receiving dexamethasone and those receiving bevacizumab (a gain of 10.4 letters (0.22 logMAR) for dexamethasone eyes versus a gain of 7.7 letters (0.13 logMAR) for bevacizumab eyes (P = 0.47)). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005656-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005656-sec-0084"></div> <section id="CD005656-sec-0085"> <h3 class="title" id="CD005656-sec-0085">Summary of main results</h3> <p>This updated review aimed to summarize medium‐ and long‐term effects of intravitreal steroids to treat DME. The key findings can be summarized as follows. </p> <p> <ol id="CD005656-list-0005"> <li> <p>Intravitreal dexamethasone implant improves VA slightly more than sham (moderate‐certainty evidence at 12 and 24 months, low‐certainty evidence at 36 months). </p> </li> <li> <p>Evidence on the effects of intravitreal dexamethasone implant versus bevacizumab or ranibizumab was inconsistent in two trials (low‐certainty evidence at 12 and 24 months), although dexamethasone might lead to greater macular thickness reduction. </p> </li> <li> <p>Intravitreal fluocinolone implant improves VA slightly more than sham (moderate‐certainty evidence at 12 and 24 months). </p> </li> <li> <p>Intravitreal triamcinolone injection may improve VA slightly more than sham (low‐certainty evidence at 24 months), and probably no more than laser photocoagulation (very low‐certainty evidence at 9‐12 months in two inconsistent trials), and less than bevacizumab (low‐certainty evidence at 12 months). </p> </li> </ol> </p> <p>Regarding adverse effects, steroids increase cataract progression and cause IOP‐related adverse events, but there was no direct comparison between different steroids. Overall: </p> <p> <ol id="CD005656-list-0006"> <li> <p>cataract progressed in about 2 out of 10 participants in the control group as compared to 5 or 6 out of 10 participants treated with steroids (moderate‐certainty evidence at 12 to 36 months); </p> </li> <li> <p>IOP increase was found in 1 in 20 participants in the control group and about 3 in 10 participants treated with steroids (moderate‐certainty evidence at 12 to 36 months); </p> </li> <li> <p>about 1 in 100 controls started IOP‐lowering medications compared to 1 in 3 treated with steroids (moderate‐certainty evidence at 12 to 36 months); </p> </li> <li> <p>less than 1% of controls received glaucoma surgery compared to 1 in 50 treated with steroids (low‐certainty evidence at 12 to 36 months); most of the evidence was based on data at 36 months from a single trial on fluocinolone implant, in which about 1 in 20 participants needed glaucoma surgery. However, the need for surgery remained rare, and all RR estimates were imprecise. </p> </li> </ol> </p> </section> <section id="CD005656-sec-0086"> <h3 class="title" id="CD005656-sec-0086">Overall completeness and applicability of evidence</h3> <p>Overall, the evidence on dexamethasone and fluocinolone implants was mostly provided by two large, multicenter, industry‐sponsored, sham‐controlled trials conducted in retina clinics (<a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>). Both of these trials excluded patients with visual field damage due to glaucoma, or uncontrolled glaucoma or ocular hypertension, which is consistent with current recommendations. In fact, the absolute risk of IOP‐related adverse events would be higher in such participants, and intravitreal steroids are generally considered to be contraindicated. </p> <p><a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a> only permitted use of intravitreal dexamethasone no more often than every six months, which may have represented undertreatment compared to current practice. On the other hand, one publicly sponsored trial, <a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>, and one industry‐sponsored trial, <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>, comparing intravitreal dexamethasone with antiVEGFs (bevacizumab and ranibizumab, respectively) permitted use of dexamethasone every 16 or 20 weeks, respectively, There is no standard regimen for intravitreal triamcinolone, which is generally used off‐label for DME. </p> <p>Planned subgroup analyses of <a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a> reported greater functional efficacy of fluocinolone implant in participants with DME for more than 36 months than in participants with more recent DME. Cataract developed about 12 months after intravitreal steroids use, which may decrease visual benefit until cataract surgery is done. Planned subgroup analyses in these trials showed better visual results in pseudophakic participants (<a href="./references#CD005656-bbs2-0005" title="CampochiaroPA , BrownDM , PearsonA , CiullaT , BoyerD , HolzFG , et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011;118(4):626-35. DempeC , SchollS , AugustinA . Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months. In: Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland. 2012. ">FAME 2011</a>; <a href="./references#CD005656-bbs2-0008" title="AugustinAJ , KuppermannBD , LanzettaP , LoewensteinA , LiXY , CuiH , et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology2015;30:150. BoyerDS , YoonYH , Belfort R Jr, BandelloF , MaturiRK , AugustinAJ , et al, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology2014;121:1904-14. MaturiRK , PollackA , UyHS , VaranoM , GomesAM , LiXY , et al, Ozurdex MEAD Study Group. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina2016;36:1143-52. ">MEAD 2014</a>). Two more trials comparing dexamethasone with antiVEGF reported data in pseudophakic participants, for whom cataract is not a concern, and also found no drop in VA in the second treatment year due to cataract progression (<a href="./references#CD005656-bbs2-0002" title="AlessandrelloEM , HodgsonLA , McAuleyAK , Fraser-BellS , GilliesMC , LimLL , et al. Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema. Clinical and Experimental Ophthalmology2015;43:117-8. Cornish, E E, Teo, K Y C, Gillies, M C, Lim, L L, McAllister, I, Sanmugasundram, S, Nguyen, V, Wickremasinghe, S, Mehta, H, Fraser-Bell, S. Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone). Investigative Ophthalmology and Visual Science2018;59(9). GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology2014;121(12):2473-81. GilliesMC , Lim Ll, CampainA , QuinG , SalemW , LiJ , et al. BEVORDEX—a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema. Investigative Ophthalmology and Visual Science2014;55(13):ARVO E-abstract 5053. ">BEVORDEX 2014</a>; <a href="./references#CD005656-bbs2-0003" title="CallananDG , LoewensteinA , PatelSS , MassinP , CorcósteguiB , LiXY , et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology2017;255(3):463-73. ">Callanan 2017</a>). </p> <p>Restriction of the indication to intravitreal steroids has been considered by regulatory agencies based on subgroup evidence from randomized controlled trials. The European Medicines Agency (EMA) has approved intravitreal dexamethasone implant 0.7 mg to treat visual impairment due to DME in people who are pseudophakic or who are considered insufficiently responsive to or unsuitable for non‐corticosteroid therapy. The UK National Institute for Clinical Excellence (NICE) has approved the use of intravitreal fluocinolone in pseudophakic eyes with chronic DME that is unresponsive to other therapy, including laser and antiVEGF injections. The US FDA originally approved intravitreal dexamethasone for use in pseudophakic patients, but then extended this indication to general DME. </p> <p>Finally, <a href="./references#CD005656-bbs2-0124" title="WeinbergT , LoewensteinA . The role of steroids in treating diabetic macular oedema in the era of anti-VEGF. Eye (London, England)2020;34:1003-5.">Weinberg 2020</a> suggested other potential indications for the use of intravitreal steroids in DME based on indirect evidence (non‐compliant patients, since fewer injections are needed) or safety concerns (pregnant women or individuals with recent arterial thromboembolic events). We did not find evidence on these issues in the included studies. </p> </section> <section id="CD005656-sec-0087"> <h3 class="title" id="CD005656-sec-0087">Quality of the evidence</h3> <p>Limitations of the evidence used in this systematic review mainly stem from the poor reporting of many of the included trials, which made 'Risk of bias' assessment difficult. </p> </section> <section id="CD005656-sec-0088"> <h3 class="title" id="CD005656-sec-0088">Potential biases in the review process</h3> <p>We followed standard Cochrane methodology in conducting this review. We could collect only partial data from subgroup analyses of the included trials, which may limit the clinical impact of our conclusions. Based on these subgroup analyses, steroids seem to be more useful in pseudophakic patients. Furthermore, for fluocinolone added to standard care, steroids might be more effective in people with chronic DME. </p> </section> <section id="CD005656-sec-0089"> <h3 class="title" id="CD005656-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>A previous meta‐analysis including only dexamethasone implant found that, compared with antiVEGF, dexamethasone implant improved anatomical outcomes significantly (<a href="./references#CD005656-bbs2-0106" title="HeY , RenXJ , HuBJ , LamWC , LiXR . A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmology2018;18(1):121.">He 2018</a>). However, the authors agreed with us that improvement in anatomical outcomes did not translate to improved VA, which may be due to the progression of cataract. The authors concluded that the dexamethasone implant may be recommended as a first choice for select cases, such as for pseudophakic eyes, antiVEGF‐resistant eyes, or patients reluctant to receive frequent intravitreal injections. </p> <p>Registries and real‐world data are important to investigate whether trial results match those obtained in clinical practice, particularly regarding safety. <a href="./references#CD005656-bbs2-0118" title="RosenblattA , UdaondoP , Cunha-VazJ , SivaprasadS , BandelloF , LanzettaP , et al. A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME registry study. Ophthalmology2020;127(3):377-93.">Rosenblatt 2019</a> reported that the optimal dexamethasone implant treatment interval is shorter than what was used in trials, since benefits peak at three months. They also observed that more patients improve with dexamethasone implant in multiple registries compared to trials, possibly due to shorter treatment intervals and better patient selection. A systematic review of real‐world studies also suggested that better visual outcomes can be achieved with dexamethasone implant with a pro re nata treatment in which injections may be delivered earlier than six months if DME recurs (<a href="./references#CD005656-bbs2-0095" title="BucoloC , GozzoL , LongoL , MansuetoS , VitaleDC , DragoF . Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. Journal of Pharmacological Sciences2018;138(4):219-32.">Bucolo 2018</a>). </p> <p><a href="./references#CD005656-bbs2-0109" title="HoldenSE , KapikB , BeiderbeckAB , CurrieCJ . Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trial. Current Medical Research and Opinion2019;35(7):1165-76.">Holden 2019</a> reported on the effects obtained in a large UK registry on fluocinolone implant and compared them with those in trials. They found VA improvement at 12 months both in the real‐world study and in the randomized controlled trials. The improvements in VA and retinal thickness in the randomized controlled trials were marginally greater than those observed in the real‐world study; however, participants in the real‐world study had more severe visual morbidity at baseline. </p> <p>Ocular adverse effects on IOP were similar for intravitreal dexamethasone and fluocinolone implants in large observational studies, <a href="./references#CD005656-bbs2-0096" title="ChakravarthyU , TaylorSR , KochFH , Castro de SousaJP , BaileyC , ILUVIEN Registry Safety Study (IRISS) Investigators Group. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. British Journal of Ophthalmology2019;103(8):1072-7.">Chakravarthy 2019</a>; <a href="./references#CD005656-bbs2-0116" title="RajeshB , Zarranz-VenturaJ , FungAT , BuschC , SahooNK , Rodriguez-ValdesPJ , et al. Safety of 6000 intravitreal dexamethasone implants. British Journal of Ophthalmology2020;104(1):39-46.">Rajesh 2020</a>, compared to the trials included in this review, and were possibly different by ethnicity (Sharma 2019). An earlier study on 421 eyes of 361 patients also found effects on IOP similar to those in our review (<a href="./references#CD005656-bbs2-0119" title="MalclèsA , DotC , VoirinN , ViéAL , Agard É, BellocqD , et al. Safety of intravitreal dexamethasone implant (Ozurdex): The SAFODEX study. Incidence and risk factors of ocular hypertension. Retina2017;37(7):1352-9.">SAFODEX 2017</a>), that is 1 in 3 patients needing IOP‐lowering medications and less than 1% needing surgery for glaucoma, all of which with pre‐existing glaucoma. They also found no harmful effect of earlier repeated dexamethasone injection at three or four months. </p> <p>In this updated review we did not extract economic data.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005656-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005656-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005656-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.1 Change in visual acuity [logMAR]." data-id="CD005656-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.1 Change in visual acuity [logMAR]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.2 Gain of three or more lines visual acuity." data-id="CD005656-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Intravitreal dexamethasone versus sham, outcome: 1.2 Gain of three or more lines visual acuity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.1 Change in visual acuity [logMAR]." data-id="CD005656-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.1 Change in visual acuity [logMAR]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.2 Gain of three or more lines visual acuity." data-id="CD005656-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Intravitreal dexamethasone versus intravitreal antiVEGF, outcome: 2.2 Gain of three or more lines visual acuity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.1 Change in visual acuity." data-id="CD005656-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.1 Change in visual acuity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.2 Gain of three or more lines visual acuity." data-id="CD005656-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Intravitreal fluocinolone implant versus other treatment, outcome: 3.2 Gain of three or more lines visual acuity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 1: Change in visual acuity" data-id="CD005656-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 1: Change in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 2: Gain of three or more lines visual acuity" data-id="CD005656-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 2: Gain of three or more lines visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 3: Change in retinal thickness" data-id="CD005656-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 3: Change in retinal thickness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 4: Cataract progression at 36 months" data-id="CD005656-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 4: Cataract progression at 36 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 5: IOP increase at 36 months" data-id="CD005656-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 5: IOP increase at 36 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 6: Use of IOP‐lowering medications at 36 months" data-id="CD005656-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 6: Use of IOP‐lowering medications at 36 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Intravitreal dexamethasone versus sham, Outcome 7: Surgery for glaucoma at 36 months" data-id="CD005656-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Intravitreal dexamethasone versus sham, Outcome 7: Surgery for glaucoma at 36 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 1: Change in visual acuity" data-id="CD005656-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 1: Change in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 2: Gain of three or more lines visual acuity" data-id="CD005656-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 2: Gain of three or more lines visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 3: Change in retinal thickness" data-id="CD005656-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 3: Change in retinal thickness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 4: Cataract progression at 12 to 24 months" data-id="CD005656-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 4: Cataract progression at 12 to 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 5: IOP increase at 24 months" data-id="CD005656-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 5: IOP increase at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 6: Use of IOP‐lowering medications at 24 months" data-id="CD005656-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 6: Use of IOP‐lowering medications at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 7: Surgery for glaucoma at 24 months" data-id="CD005656-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Intravitreal dexamethasone versus intravitreal antiVEGF, Outcome 7: Surgery for glaucoma at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 1: Change in visual acuity" data-id="CD005656-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 1: Change in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 2: Gain of three or more lines visual acuity" data-id="CD005656-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 2: Gain of three or more lines visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 3: Change in central retinal thickness" data-id="CD005656-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 3: Change in central retinal thickness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 4: Cataract progression at 24 months" data-id="CD005656-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 4: Cataract progression at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 5: IOP increase at 24 months" data-id="CD005656-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 5: IOP increase at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 6: Use of IOP‐lowering medications at 24 months" data-id="CD005656-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 6: Use of IOP‐lowering medications at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 7: Surgery for glaucoma at 24 months" data-id="CD005656-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Intravitreal fluocinolone acetonide implant versus sham, Outcome 7: Surgery for glaucoma at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 1: Change in visual acuity" data-id="CD005656-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 1: Change in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 2: Gain of three or more lines visual acuity" data-id="CD005656-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 2: Gain of three or more lines visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 3: Change in retinal thickness" data-id="CD005656-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 3: Change in retinal thickness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 4: Cataract progression at 24 months" data-id="CD005656-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 4: Cataract progression at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 5: IOP increase at 24 months" data-id="CD005656-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 5: IOP increase at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 6: Use of IOP‐lowering medications at 24 months" data-id="CD005656-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 6: Use of IOP‐lowering medications at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 7: Surgery for glaucoma at 24 months" data-id="CD005656-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Intravitreal triamcinolone acetonide injection versus sham, Outcome 7: Surgery for glaucoma at 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 1: Change in visual acuity" data-id="CD005656-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 1: Change in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 2: Gain of three or more lines visual acuity" data-id="CD005656-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 2: Gain of three or more lines visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 3: Change in central retinal thickness" data-id="CD005656-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 3: Change in central retinal thickness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 4: Cataract progression at 9 to 24 months" data-id="CD005656-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 4: Cataract progression at 9 to 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 5: IOP increase at 9 to 24 months" data-id="CD005656-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 5: IOP increase at 9 to 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 6: Use of IOP‐lowering medications at 9 to 24 months" data-id="CD005656-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 6: Use of IOP‐lowering medications at 9 to 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 7: Surgery for glaucoma at 9 to 24 months" data-id="CD005656-fig-0043" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Intravitreal triamcinolone acetonide versus laser photocoagulation, Outcome 7: Surgery for glaucoma at 9 to 24 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Intravitreal triamcinolone acetonide versus antiVEGF, Outcome 1: Change in visual acuity at 12 months" data-id="CD005656-fig-0044" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Intravitreal triamcinolone acetonide versus antiVEGF, Outcome 1: Change in visual acuity at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005656-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/urn:x-wiley:14651858:media:CD005656:CD005656-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Intravitreal triamcinolone acetonide versus antiVEGF, Outcome 2: Change in central retinal thickness at 12 months" data-id="CD005656-fig-0045" src="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_t/tCD005656-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Intravitreal triamcinolone acetonide versus antiVEGF, Outcome 2: Change in central retinal thickness at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/media/CDSR/CD005656/image_n/nCD005656-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005656-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravitreal dexamethasone implant 0.7 mg compared to sham for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal dexamethasone implant 0.7 mg compared to sham for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal dexamethasone implant 0.7 mg<br/><b>Comparison:</b> sham </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal dexamethasone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity ‐ 12 months was 0.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.08 better<br/>(−0.12 better to −0.05 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE 1 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000<br/>(86 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.39<br/>(0.91 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE 1 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change of retinal thickness ‐ 36 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness (micron) ‐ 36 months was −51.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −81 micron</p> <p>(−100 to −63 micron)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>97 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>378 per 1000</p> <p>(267 to 534)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.89</p> <p>(2.75 to 5.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>415 per 1000</p> <p>(292 to 591)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.54</p> <p>(3.19 to 6.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> <p>(1 to 43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.04</p> <p>(0.59 to 42.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>2</sup>Downgraded −1 for risk of bias: large loss to follow‐up. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravitreal dexamethasone implant 0.7 mg compared to sham for macular edema in diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005656-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravitreal dexamethasone implant 0.7 mg compared to intravitreal antiVEGF for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal dexamethasone implant 0.7 mg compared to intravitreal antiVEGF for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal dexamethasone implant 0.7 mg<br/><b>Comparison:</b> intravitreal antiVEGF </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of eyes<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal antiVEGF</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal dexamethasone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity ‐ 12 months was −0.16.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 worse<br/>(0.04 worse to 0.09 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Inconsistent findings: one trial finding no evidence of a difference between dexamethasone and bevacizumab at 12 months (RR 0.99, 95% CI 0.70 to 1.40; 1 trial; 88 eyes), and the other found the chances of vision gain were half with dexamethasone compared with ranibizumab (RR 0.50, 95% CI 0.32 to 0.79; 1 trial; 432 eyes). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness ‐ 12 months was −140.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −21.09 thinner<br/>(−41.9 thinner to −0.28 thinner) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> <p>(68 to 246)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.23</p> <p>(2.36 to 7.59)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE 1 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> <p>(234 to 659)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.76</p> <p>(2.84 to 7.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> <p>(26 to 44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.02</p> <p>(0.12 to 73.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>antiVEGF:</b> anti‐vascular endothelial growth factor agent; <b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high or unclear risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>3</sup>Downgraded −1 for inconsistency: heterogeneous results of two trials.<br/><sup>4</sup>Downgraded −2 for imprecision: very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravitreal dexamethasone implant 0.7 mg compared to intravitreal antiVEGF for macular edema in diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005656-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Intravitreal fluocinolone acetonide implant 0.19 mg compared to sham for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal fluocinolone implant 0.19 mg compared to sham for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal fluocinolone acetonide implant 0.19 mg<br/><b>Comparison:</b> sham </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal fluocinolone implant</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity was −0.04.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.04 better<br/>(−0.06 better to −0.01 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>213 per 1000<br/>(138 to 331) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.79<br/>(1.16 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness was −67.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −76.00 thinner</p> <p>(−94.31 thinner to −57.69 thinner)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>560<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>815 per 1000<br/>(675 to 985) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.63<br/>(1.35 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>355<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>264 per 1000</p> <p>(384 to 562)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.72</p> <p>(1.87 to 3.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>558<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> <p>(7 to 385)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 9.54</p> <p>(1.28 to 70.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>558<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: unclear risk of bias for most domains.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Intravitreal fluocinolone acetonide implant 0.19 mg compared to sham for macular edema in diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005656-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to sham for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal triamcinolone acetonide injection 4 mg compared to sham for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal triamcinolone acetonide injection 4 mg<br/><b>Comparison:</b> sham </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of eyes<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sham</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal triamcinolone injection</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 24 months**</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity was −0.02.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −0.11 better<br/>(−0.20 better to −0.03 better) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 24 months**</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/>(14 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.12<br/>(0.48 to 34.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron) ‐ 24 months**</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in retinal thickness was −71.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD −59 thinner<br/>(−103.5 thinner to −14.5 thinner) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000<br/>(139 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/>(0.97 to 9.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000</p> <p>(384 to 562)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 21.60</p> <p>(1.32 to 354.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No surgeries were recorded in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>**No data available at 12 months. </p> <p><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>3</sup>Downgraded −2 for imprecision: very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to sham for macular edema in diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005656-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to macular laser for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal triamcinolone acetonide injection 4 mg compared to macular laser for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal triamcinolone acetonide injection 4 mg<br/><b>Comparison:</b> macular laser </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of eyes<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with macular laser</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal triamcinolone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>1 small study (31 participants) reported data favoring triamcinolone at 9 months (MD −0.18, 95% CI −0.29 to −0.07), and data from a large, multicenter study (584 eyes) favored macular laser at 12 months (MD 0.02, 95% CI −0.03 to 0.07). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity ‐ 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000</p> <p>(77 to 182)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85</p> <p>(0.55 to 1.30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>584</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in retinal thickness (micron)</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>1 small study (31 participants) reported data favoring triamcinolone at 9 months (MD −83.00, 95% CI −171.60 to −5.60), and data from a large, multicenter study (454 participants) found no difference between groups at 12 months (MD 5.00, 95% CI −18.76 to 28.76). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression ‐ 9 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>767 per 1000<br/>(633 to 927) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.68</p> <p>(2.21 to 3.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications ‐ 9 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>279 per 1000</p> <p>(184 to 425)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.92</p> <p>(2.59 to 5.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma ‐ 9 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> <p>(1 to 216)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 11.68 (0.63 to 216)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −2 for inconsistency: significant heterogeneity between studies.<br/><sup>3</sup>Downgraded −1 for imprecision: large confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to macular laser for macular edema in diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005656-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to antiVEGF for macular edema in diabetes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Intravitreal triamcinolone acetonide injection 4 mg compared to antiVEGF for macular edema in diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> macular edema in diabetes<br/><b>Setting:</b> retina clinics<br/><b>Intervention:</b> intravitreal triamcinolone acetonide injection 4 mg<br/><b>Comparison:</b> antiVEGF </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with antiVEGF</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with intravitreal triamcinolone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in visual acuity (logMAR) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in visual acuity ‐ 12 months was −0.12 logMAR.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.18 worse<br/>(0.10 worse to 0.26 worse) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gain of three or more lines visual acuity</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in central retinal thickness (micron) ‐ 12 months</p> <p>(negative is better)</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Inconsistent, non‐significant effects were found for triamcinolone versus bevacizumab or ranibizumab. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataract progression</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of IOP‐lowering medications</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No data reported on IOP‐lowering medications, but the authors state that there was no difference in IOP change in the triamcinolone and bevacizumab groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Surgery for glaucoma</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No surgery for glaucoma reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>antiVEGF:</b> anti‐vascular endothelial growth factor agent; <b>CI:</b> confidence interval; <b>IOP:</b> intraocular pressure; <b>MD</b> : mean difference; <b>RCT:</b> randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded −1 for risk of bias: high risk of bias for at least one domain.<br/><sup>2</sup>Downgraded −1 for imprecision: wide confidence intervals.<br/><sup>3</sup>Downgraded −2 for inconsistency: heterogeneous results of two antiVEGF study arms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection 4 mg compared to antiVEGF for macular edema in diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/full#CD005656-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005656-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravitreal dexamethasone versus sham</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Gain of three or more lines visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Cataract progression at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 IOP increase at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Use of IOP‐lowering medications at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Surgery for glaucoma at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intravitreal dexamethasone versus sham</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005656-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravitreal dexamethasone versus intravitreal antiVEGF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.04, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.03, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Gain of three or more lines visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.09 [‐41.90, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐109.00 [‐171.37, ‐46.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Cataract progression at 12 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.23 [2.36, 7.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 IOP increase at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [1.53, 5.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Use of IOP‐lowering medications at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.76 [2.84, 7.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Surgery for glaucoma at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravitreal dexamethasone versus intravitreal antiVEGF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005656-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intravitreal fluocinolone acetonide implant versus sham</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Gain of three or more lines visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Change in central retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Cataract progression at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 IOP increase at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Use of IOP‐lowering medications at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Surgery for glaucoma at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intravitreal fluocinolone acetonide implant versus sham</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005656-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection versus sham</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>MD (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Gain of three or more lines visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Change in retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Cataract progression at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 IOP increase at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Use of IOP‐lowering medications at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Surgery for glaucoma at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Intravitreal triamcinolone acetonide injection versus sham</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005656-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Intravitreal triamcinolone acetonide versus laser photocoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Change in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 At 9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Gain of three or more lines visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Change in central retinal thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 At 9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Cataract progression at 9 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [2.21, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 IOP increase at 9 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.62 [5.44, 17.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Use of IOP‐lowering medications at 9 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [2.59, 5.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Surgery for glaucoma at 9 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.68 [0.63, 215.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Intravitreal triamcinolone acetonide versus laser photocoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005656-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Intravitreal triamcinolone acetonide versus antiVEGF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Change in visual acuity at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.10, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Comparator: bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Comparator: ranibizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.08, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Change in central retinal thickness at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Comparator: bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Comparator: ranibizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Intravitreal triamcinolone acetonide versus antiVEGF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005656.pub3/references#CD005656-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005656.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005656-note-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005656-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005656-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005656-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005656-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD005656-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005656-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005656\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005656\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005656\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005656\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005656\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005656.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005656.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005656.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005656.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005656.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726285344"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005656.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726285348"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005656.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8fe71980f431',t:'MTc0MDcyNjI4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 